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Abstract 
 Chronic liver diseases, which includes alcoholic liver disease (ALD), are consistently 
among the top 15 leading causes of death in the United States. ALD is characterized by 
progression from a normal liver to fatty liver disease (hepatic steatosis), which can lead to 
cirrhosis, alcoholic hepatitis, and liver failure. We have identified a novel role of phosphohistidine 
signaling, mediated through phosphohistidine phosphatase 1 (PHPT1), in the onset of hepatic 
steatosis. We have identified PHPT1 as a target of selective oxidation following acute ethanol 
exposure as well as being downregulated following chronic ethanol exposure. We mapped the 
oxidative modification site and developed a mass-spectrometry based phosphohistidine 
phosphatase assay to determine the impact of PHPT1 oxidative modification during acute 
ethanol exposure. To further understand the role of PHPT1 and phosphohistidine signaling 
during chronic ethanol exposure, we have developed PHPT1 overexpression and knockout 
mouse models. These mouse models were characterized using mass spectrometry-based 
proteomics. They were then utilized in a 10-day chronic ethanol plus binge model to determine 
the impact of PHPT1 expression on the onset of ethanol-induced hepatic steatosis. In addition, 
advanced mass spectrometry-based phenotypic characterization was performed on the treated 
liver tissues to determine the key regulators and canonical pathways influencing 
phosphohistidine signaling during chronic ethanol exposure. We have evidence to suggest that 
PHPT1 overexpression plays a protective role in the onset of hepatic steatosis, the PHPT1 
heterozygous model is more susceptible to liver damage, and the complete knockout model is 
embryonically lethal. Additionally, we have identified novel pathways and regulators involved in 
phosphohistidine signaling during the development of ethanol-induced hepatic steatosis.  
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Chapter 1 – Introduction 
Alcoholic liver disease 
  Alcoholic liver disease (ALD) categorizes a plethora of specific conditions, including 
fatty liver, steatohepatitis, and cirrhosis. In addition, patients are more susceptible to non-
alcoholic related diseases such as non-alcoholic fatty liver disease, and chronic viral hepatitis 
when developing ALD. A combination of these diseases, including obesity, significantly 
increases a patient’s risk for developing cancer or liver failure. Alcohol can be contributed to 
44% of all liver disease related deaths in 2003 [1], while liver cirrhosis was the 12th leading 
cause of death in the United states in 2010 [2]. This is largely due to the prevalence and 
socioeconomic burden of alcoholism. The consumption of ethanol can be traced back for 
centuries when fermentation was necessary for disinfection [3]. Alcohol is a psychoactive drug 
which means it alone can lead to dependence. It has been classified by the World Health 
Organization to be among the top five leading risk factors for disease/disability and death in 
2011 [4, 5]. In 2013, alcohol was number 4 of the 10 leading level 3-risk factors in developed 
countries for both sexes in terms of attributable deaths, years of life lost, years lived with 
disability, and disability-adjusted life-years [6]. Alcohol use, in general, accounted for 2.8 million 
deaths in 2013 which was an increase in total and percent deaths from previous years [6]. The 
wide prevalence of alcohol use, as well as its great burden of disease and death around the 
world is the sole contributor to the development of alcoholic liver disease. 
 Alcohol consumption is generally classified by binge, chronic, or moderate consumption. 
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) classifies binge drinking as 
bringing one’s blood alcohol concentration (BAC) greater than or equal to 0.08 g/dl. This is also, 
classified by the Substance Abuse and Mental Health Services Administration (SAMHSA) as 
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having more than 4-5 drinks in one day or occasion. Chronic drinking is considered by the 
SAMHSA as having more than 4-5 drinks in one occasion 5 or more times over a 30-day period. 
Moderate or low risk consumption is considered anything less than binge drinking in a single 
day or 7/14 drinks per week for women/men, respectively. Although actual consumption may 
vary amongst individuals, these consumption classifications are widely used to classify different 
models of consumption and their effects on disease progression. Chronic and binge drinkers are 
considered most at risk for disease development. Alcohol has been linked to disease 
development in almost every organ system in the human body. This includes gastrointestinal 
complications in the stomach, pancreas, and colon, as well as heart disease and muscle 
degeneration [7]. The brain and the liver however, are the two most commonly discussed 
organs associated with heavy alcohol consumption. The brain is probably the most effected 
organ given that changes in judgement can occur with a BAC as low as 0.02 g/dl, followed by 
impairment of motor functions and reaction time occurring between 0.06-0.10 g/dl, with cognitive 
ability and involuntary muscle impairment setting in around a 0.15-0.20. A BAC higher than this 
is associated with immediate permanent brain damage and can also result in death. The other 
main organ directly affected by alcohol consumption is the liver. As the main filtration system for 
removing alcohol from the blood stream, the liver undergoes a great amount of ethanol-induced 
stress in both chronic and binge drinkers. ALD is generally a progression from mild and 
asymptomatic, to severe and life threatening (Figure 1).  
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When it comes to disease progression, moderate consumption rarely leads to any 
disease onset. However, it is estimated that 90% of individuals who are considered chronic 
drinkers will develop steatosis [8]. This is classified by the enlargement of the liver and 
histologically by the presence of lipid droplets in the hepatocytes. This injury can also be 
accompanied by inflammation, which usually suggests a more severe condition developing. If 
drinking persists 35% of those individuals will progress to steatohepatitis and up to 20% will 
develop liver cirrhosis without first experiencing steatohepatitis. Steatohepatitis shows more 
exacerbated symptoms to that of steatosis, with the increase in size and quantity of lipid 
droplets, development of inflammation, hepatocyte necrosis, as well as Mallory bodies [9]. Up to 
70% of those who do not abstain from alcohol following development of steatohepatitis will 
progress to cirrhosis. Even of those that do abstain after the development of steatohepatitis only 
roughly 27% will recover fully to a normal liver, whereas 18% will develop cirrhosis regardless 
[10]. Cirrhosis is characterized by the deposition of extracellular matrix proteins via the onset of 
widespread fibrosis and inflammation throughout the liver. This condition is also accompanied 
by hepatocellular necrosis and predominantly macronodular development [9].  
 Disease prognosis depends on the stage of progression with fewer viable options as the 
severity increases. If caught in the early stages of steatosis and fatty liver development, the 
conditions are completely reversible with abstinence. However, the likelihood of full recovery 
decreases with steatohepatitis and once cirrhosis begins to develop complete recovery from 
abstinence alone is rare. Generally, treatment with corticosteroids or pentoxifylline is necessary 
once the disease has progressed to steatohepatitis [11, 12]. These treatments are also limited 
in their effectiveness. In many cases the only option for full recovery is a liver transplant. To 
receive a transplant, the patient must be able to prove at least 6 months of abstinence to be 
placed on the waiting list. The patient could then potentially wait years for a liver from a 
compatible donor to become available. In addition, liver transplant surgery has its own risks, 
with potential physiological rejection of a donor liver. These conditions make it very difficult for 
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patients with late stage ALD to fully recover, often requiring them to undergo regular blood 
transfusions to overcome symptoms associated with decreased liver function.  Furthermore, 
with development of cirrhosis comes an increase in likelihood for liver cancer and malignancies 
that can cause complications elsewhere. Ideally, prevention and early identification of this 
disease is best. Prevention can obviously be accomplished through absolute abstinence or even 
moderate drinking. In addition, a diet with high antioxidants has also been shown to play a 
protective role in disease onset [11]. Unfortunately, early detection is difficult because often, 
fatty liver disease is asymptomatic and can only be confirmed with a histologically stained 
biopsy [13]. This makes identifying circulating biomarkers and molecular determinants of 
disease critical for treatment. Disease onset is further complicated by the multiple mechanisms 
involved in disease pathogenesis.  
 Ethanol pathogenesis involves a plethora of pathways and cellular response activated 
following consumption (Figure 2). In addition, the expression level and effectiveness of these 
pathways change as consumption increases. This coincides with the higher correlation in risk 
factors seen in chronic drinkers, as compared to moderate. Initially, ethanol is primarily 
processed and metabolized in the liver. Only about 10% of ethanol consumed is lost directly 
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through sweat, lung, and kidneys [14]. Hepatocytes are the resident cells of the liver that 
primarily metabolize ethanol due to their expression all three of the enzymes essential for 
ethanol metabolism. Catalase is one of these enzymes, however, it is strictly expressed within 
peroxisomes [15], so ethanol metabolism is primarily mediated by alcohol dehydrogenase in the 
cytosol and cytochrome P450 2e1 (CYP2E1) within the endoplasmic reticulum (ER) [15-17]. 
Both enzymes yield acetaldehyde from the reaction, as well as generate the reduced form of 
nicotinamide adenine dinucleotide (NAD+/NADH), and nicotinamide adenine dinucleotide 
phosphate (NADP+/NADPH), respectively. The presence of acetaldehyde can lead directly to 
stress on the cell in the form of reactive oxygen species (ROS). Acetaldehyde and ethanol are 
directly involved in the creation of ROS such as hydrogen peroxide (H2O2) and superoxide anion 
(O2-) [18]. Fortunately, acetaldehyde is converted into acetate by aldehyde dehydrogenase 
which has high expression in hepatocytes and results in the creation of an additional NADH. 
Initially, CYP2E1 only accounts for 10% of ethanol metabolism, but is substrate induced and 
increases expression in chronic ethanol users [16, 17]. In addition, high frequency of ethanol 
metabolism leads to an accumulation of NADH. This not only inhibits aldehyde dehydrogenase, 
which results in more ROS via acetaldehyde accumulation, but also interferes with the citric acid 
cycle (the main route for acetate metabolism), causing an overall increase in acetyl-CoA present 
in the cell [13]. Both increased ROS production and acetyl-CoA accumulation will cause 
significant downstream influences on hepatocyte function. 
 The presence of hydrogen peroxide and superoxide anion (known ROS) can create 
even more hazardous free radicals and ferric oxide ions [19]. These highly reactive species lead 
directly to protein oxidation, and cause stress on organelles, like the ER and the mitochondria. 
The primary source of protection against ROS are free radical scavenging proteins such as 
glutathione, epoxide hydrolase 1 (EPHX1) [20-23], and heme oxygenase-1 (HO1) in the ER 
[24]. When ethanol exposure continues, however, the protective role of these proteins becomes 
diminished, as they are oxidized leaving the cell susceptible to oxidation-mediated damage. 
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ROS is directly created in the ER through CYP2E1 metabolization of ethanol, resulting in 
acetaldehyde formation. Protein oxidation in the ER can lead directly to accumulation of 
unfolded proteins. The cell reacts by activating NF-κβ and JNK, leading to an inflammatory 
response [25, 26]. In addition, unfolded proteins can stimulate the phosphorylation of Interferon 
regulatory factor 3 (IRF3), which will stimulate mitochondrial stress via caspase activation [27].  
 These insults, will further activate the steatogenic pathway through sterol regulatory 
element-binding protein (SREBP) activation, specifically SREBP1c [28, 29]. This pathway is 
primarily regulated by adenosine monophosphate-activated protein kinase (AMPK) signaling, 
which is inhibited directly by ethanol and acetaldehyde and indirectly via TNF (Tumor necrosis 
factor) signaling [30]. TNF is released from adipose tissue following ethanol-mediated 
inflammation [31]. Inhibition of AMPK activates SREBP1c and inhibits protective regulators, 
such as peroxisome proliferator-activating receptor α (PPARα) and the RXR-α pathway [13, 32-
34]. This alteration in lipid homeostasis results in an increase in lipogenesis, via SREBP1c 
activation of fatty acid synthase (FASN), and a decrease in lipid oxidation, which is necessary 
for export. This outcome is additionally accompanied by an increase in acetyl-CoA present due 
to inhibition of the Krebs cycle. This is mediated through the inhibition of isocitrate 
dehydrogenase due to the NAD+/NADH imbalance in the cell. The resulting accumulation of 
citrate is then exported back into the cell in the form of acetyl-CoA by ATP-citrate lyase (ACL), 
which is regulated by a phosphohistidine modification [35]. This influx in the acetyl-CoA pool is 
not only utilized for fatty acid synthesis, but it is also needed for protein acetylation. Histone 
acetyl transferases (HATs), such as EP300, are stimulated by an increase in the acetyl-CoA 
pool. This results in an increase in histone acetylation, which is known to activate protein 
transcription.  Concurrent pressure on the cell to increase lipogenesis, decrease fatty-acid 
oxidation, and increase transcription leads directly to the onset of fibrosis. Consistent activation 
of these pathways results in the disease progression from fatty liver/steatosis to more severe 
steatohepatitis and cirrhosis. 
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Phosphohistidine phosphatase 1 
 Phosphatases and kinases have been widely studied in mammalian and other cellular 
models. These enzymes are responsible for the addition or removal of phosphate molecules to 
protein targets. This modification has been shown to be a major player in a plethora of cellular 
pathways, including cell metabolism, signal transduction, and transcription initiation. The most 
familiar forms of phosphorylation occur on threonine, tyrosine, and serine residues. Their roles 
in numerous cascades and protein function alterations have been widely studied and examined. 
The significance of phosphohistidine, however, has been relatively uninvestigated. The gap in 
knowledge around this modification can be mostly attributed to its unstable nature and 
challenges in isolation, rather than its possible limited importance in cellular function when 
compared to other well-investigated residues. The importance of phosphohistidine is already 
highlighted in the few, yet critical targets that have been identified to date. Phosphohistidine was 
first identified as an enzymatic intermediate for phosphoryl group transfer between enzymes 
[36]. It has further been identified as a lasting modification which regulates targets such as ATP-
citrate lyase (ACL) [35], G-protein (β subunit) [37], Histone H4 [38] and KCa3.1 [39]. The 
development and loss of this modification on these targets can be attributed to phosphohistidine 
kinases and phosphatases. However, to this date, only a few of them have been identified in 
mammalian cells. Examples of these include nucleoside diphosphate kinase (NDPK), which has 
phosphohistidine kinase activity [40], as well as phosphohistidine phosphatase 1 (PHPT1) [41] 
and others [42]. 
 PHPT1 is a 14kDa protein identified in porcine liver in 2002 with phosphatase activity for 
phosphohistidine residues [41]. It has also been shown to poses dephosphorylation activity for 
phosphoramidate [43] and phospholysine in vitro [44]. PHPT1 regulation of phosphohistidine 
levels include activation/deactivation of known phosphohistidine targets. PHPT1 expression has 
been linked to ACL function in multiple studies. Human-PHPT1 overexpression in murine 
neuroblastoma cells was shown to decrease ACL activity and lead to a decrease in cell viability 
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[45]. However, the same group showed two years later that siRNA-mediated knockdown of 
PHPT1 decrease ACL expression in pancreatic β-cell islets, and PHPT1 expression had no 
impact on cell viability [46]. Although, these studies seem conflicting, they do show PHPT1 
expression to be an important regulator in ACL function. In addition, PHPT1 was also shown as 
an important regulator in the activation of G-protein during nutrient-induced insulin secretion 
[46].They showed that siRNA knockdown of PHPT1 reduced glucose-induced insulin secretion, 
but had no effect on KCL-induced secretion. This finding suggests PHPT1 was involved in G-
protein-signaling steps to mediate insulin secretion. It is known that G-protein has a key 
phosphorylation site at His266 that is a target of NDPK and PHPT1 [47]. Although the 
significance of this modification is not fully understood, it is believed to be necessary for G-
protein β/γ coupling to activate the holoenzyme [37]. PHPT1 plays an inhibitory role in the KCa 
3.1 potassium ion channel where histidine phosphorylation is necessary for the channels 
activation [39]. Histone H4 regulation is unknown but it has been identified as a target for 
PHPT1 in vitro in many studies [38, 43, 48].  
 It is clear that PHPT1 and phosphohistidine are not involved in just a singular pathway in 
mammals. PHPT1 is part of the Janus family of proteins and is the only phosphohistidine 
phosphatase part of this family identified to date. This characterization is according to the family 
domain classification available on the universal protein resource (uniport.org). The Janus family 
proteins are best characterized by their involvement in sex differentiation in Drosophila 
melanogaster [49]. PHPT1 and NDPK have been identified as players in disease progression as 
well such as hepatocellular carcinoma (HCC), meningiomas, and lung cancer [50-53]. However, 
the role of PHPT1 in each disease does not coincide across all conditions and cell types. 
PHPT1 knockdown in lung cancer cells resulted in an inhibition of migration and invasion 
mediated through actin cytoskeletal rearrangement modulation [51]. PHPT1 expression was 
shown to be elevated in HCC tissues as well as in meningiomas [52, 53]. In HCC, siRNA 
mediated knockdown of PHPT1 resulted in an increase in apoptosis and inhibited cell 
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proliferation as the G1-S phase transition [52]. In addition, according to The Cancer Genome 
Atlas, PHPT1 has been shown to be amplified in multiple cancers, most notably in 
neuroendocrine prostate cancer (Trento/Cornell/ Broad, 2016) and pancreatic cancer (UTSW 
cancer center). PHPT1 seems to be influencing many different pathways in the cell which gives 
insight into the significance of the phosphohistidine modification itself.  
Phosphohistidine signaling 
 The phosphohistidine modification was initially published in 1962 and first described in 
bovine mitochondria [36]. Since this time, there has been relatively little investigation in the 
significance of this modification in mammals as compared to tyrosine, threonine, or serine 
phosphorylation. This finding is in spite of the fact that it has been estimated that 
phosphohistidine accounts for 6% of protein phosphorylation in eukaryotic cells [54], which is 
two-fold more abundant than phosphotyrosine [55]. The main reason for the disparity in study of 
this modification is its hydrolytic lability which is much higher than the better studied forms of 
phosphorylation. This makes the modification very unstable in neutral conditions and even more 
so in acidic environments, with a half-life of less than 30 seconds in 1M HCL [56]. In addition, 
the modification can occur in two different conformations, at the 1N or at the 3N, of the 
imidazole ring on histidine (Figure 3). The first discovery was on the 1N of the ring where it 
played an intermediate role carrying a phosphoryl group between a substrate and the 
phosphate donor on kinases and phosphatases [36]. This conformation has functioned in this 
manner in many cases [56, 57]. The 3N location however has been identified as the location of 
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the lasting modification that influences enzymatic activity on known targets such as ACL [35],  
G-proteinβ [37], and KCa3.1 [39], in addition to two component histidine kinase 
autophosphorylation that occurs in Escherichia coli in vivo, and on Suc-AHPF-pNA and H4 [38] 
in vitro. The function of phosphohistidine has been best characterized in bacterial and plant cells 
[58], and their two component histidine kinase systems are well known for their regulation of cell 
signaling and transcription[59]. Most of these studies, however, have investigated 
phosphohistidine in a targeted manor. Targeted investigation is necessary because standard 
cell lysis procedures, as well as mass spectrometry sample preparations, call for acidic 
solutions and can result in complete loss of the modification before measurements are taken 
[60]. Although these pathways are not present in mammalian cells, studies have shown 
phosphohistidine levels to be significantly altered in diseases, including cancer, and to be 
involved with a diverse list of pathways [61]. Recently, the development of pan-phosphohistidine 
antibodies and phosphohistidine sensitive protocols have allowed the significance modification 
to be further investigated. 
Structure  
 To date there have been three main studies on the structure of PHPT1 and the residues 
involved in substrate binding [57, 62, 63]. All studies have shown the primary and crystalline 
structure of PHPT1 being highly conserved between mammals (Figure 4). The secondary 
structure is composed of six β-stands, which are flanked by two α-helices and short 
unstructured regions at the C- and N-terminals, 4 and 5 amino acids long, respectively [54]. 
Mutagenesis and NMR studies identified H53A in human PHPT1 to be catalytically inactive [56]. 
Other mutations that resulted in a significant decrease in kcat were M95D, A96D, K21A, and 
S94A [56]. It was concluded that the substrate binding site was located at α1 and β4 on one 
side and α2 and β5 on the other [55]. The residues involved directly in this region were Glu51, 
Tyr52, His53, Try92, and Met95 [55]. Ser94 was determined to assist with phosphate 
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stabilization via the -OH side chain [55]. His53 was determined to be the bound amino acid 
during phosphoryl group transfer between substrate and donor [54-56]. In addition, the His53 
was shown to stabilize the binding site via H53A mutagenesis causing destabilization of this 
area [62]. All studies showed H102A mutagenesis to influence substrate binding as well, even 
though it is located far away from the binding region [54-56]. This influence was determined to 
be a result of its location in a highly hydrophobic core region of the protein. H103A-mediated 
destabilization of the core region, had global protein conformational consequences resulting in a 
decrease in catalytic efficiency [55].  
 Unfortunately, these studies were limited to PHPT1 function toward peptide or molecular 
substrates, and not full protein interactions. Additionally, there have been no studies 
investigating the binding mechanism of PHPT1 toward the N-ε-phosphorylation of lysine which it 
was recently determined to target [44]. The influence of post-translational modifications on 
PHPT1 activity is relatively uninvestigated. To date, only two modifications have been 
characterized on PHPT1. One of these is an N-terminal protein acetylation [64] that occurs on 
PHPT1 following N-terminal methionine cleavage. The other modification, which was 
characterized in this dissertation, is Met95 oxidation which occurs via oxidative stress [65]. 
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Initial hypothesis of alcoholic liver disease pathogenesis  
 As discussed previously (Chap. 1 Alcoholic liver disease), there are multiple pathogenic 
pathways involved in the onset of the ALD. The main pathways include oxidative stress that 
causes an accumulation of ROS and can directly cause necrosis and apoptotic cell death. In 
addition, the influx of acetyl-CoA, as well as signals from adipose tissue, lead to an increase in 
lipid synthesis and a decrease in fatty acid oxidation. This change results in lipid accumulation 
and the ethanol-induced hepatic steatosis phenotype. Both ROS and lipid accumulation 
contribute to an increase in inflammation and protein transcription. This phenotype contributes 
to the development of more severe conditions, such as cirrhosis or hepatocellular carcinoma via 
cell differentiation. Many players in these pathways are known but progression and mechanism 
of development still needs to be further investigated. Our investigation aims to identify novel 
players in the onset of alcohol-induced hepatic steatosis and determine the mechanism in which 
they are involved in disease progression.  
 A known key player in ethanol metabolism, ACL, is responsible for the conversion of 
citrate into acetyl-CoA and oxaloacetate, and the reverse reaction. This reaction is necessary 
following accumulation of citrate caused by citric acid cycle inhibition, which can come from 
chronic ethanol ingestion that creates a high ratio of NADH:NAD+. In the later instance, the 
synthesized oxaloacetate can be converted into malate by cytosolic malate dehydrogenase, 
which utilizes the high concentration of NADH available to create NAD+. Malate can then return 
back to the citric acid cycle within the mitochondria and be oxidized again to oxaloacetate to 
maintain the function of the electron transport chain. This conversion prevents further 
accumulation of NADH, but results in additional accumulation of acetyl-CoA. Acetyl-CoA 
accumulation leads directly to fatty acid synthesis as well as histone acetylation. This result in 
combination with ROS-induced inhibition of fatty-acid oxidation results in the lipid accumulation 
responsible for the ethanol-induced hepatic steatosis phenotype. ACL is known to be 
transcriptionally induced by insulin and glucose. These molecules simultaneously activate the 
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PI3K/Akt pathway which is known to phosphorylate and activate ACL. In addition, PHPT1 
overexpression and siRNA-mediated knockdown models have been shown to directly impact 
ACL activity. ACL is a known target of phosphohistidine modification and PHPT1 
dephosphorylation. 
 Our initial hypothesis was that the regulation of ACL by PHPT1 was being influenced 
following acute or chronic ethanol exposure. We hypothesized that ethanol-induced factors such 
as ROS were altering PHPT1 activity via modification or expression levels which decreased 
regulation of ACL. Furthermore, we wanted to investigate the role of PHPT1 in the onset of 
alcohol-induced hepatic steatosis. In addition to ACL, we believed there are many other factors 
PHPT1 and phosphohistidine modification influenced that were involved in the onset of ALD. 
Despite this, the role of PHPT1 and the significance of phosphohistidine signaling following 
ethanol-induced hepatic steatosis has not been investigated. Although, as previously 
mentioned, PHPT1 has been identified to be involved in other diseases, such as 
neuroendocrine prostate cancer, and lung cancer [51, 66]. 
Other roles of PHPT1  
 Beyond the previously mentioned known targets, there have been many additional 
suggestions into the role of PHPT1. As previously mentioned from a domain standpoint, PHPT1 
fits in the Janus family of proteins. This family is best characterized in Drosophila melanogaster 
as being involved in sex differentiation and development. It is likely that PHPT1 plays a role in 
cell differentiation in mammals as well. This theory is further supported by PHPT1 being linked 
to cancer development in multiple studies. In lung cancer, it is believed to be involved in cell 
migration through actin cytoskeleton rearrangement. Furthermore, the expression of PHPT1 in 
lymph nodes and lung cancers correlated with the severity of the cancer from human samples 
[51, 66]. PHPT1 is believed to be influencing tumor progression through NF Kappa B signaling 
pathway by inducing MMP9 [67]. These studies suggest that PHPT1 plays a major role overall 
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in cancer progression and cellular homeostasis although there are no currently known targets to 
suggest this.  
 In addition, relatively little is known about PHPT1 regulation. Studies have shown broad 
expression regulators, such as HNF4α, to influence PHPT1 expression [68]. HNF4α is a key 
regulator of many proteins involved in lipid homeostasis [69]. These include the PXR and RXR 
pathways, which interact with the acetyl-CoA pool and contribute to fatty acid metabolism [70, 
71]. PHPT1 may be involved in this regulation through its interaction with ACL or other unknown 
targets involved in lipid metabolism. In addition, expression levels have also been shown to 
correlate with phosphohistidine kinases, such as nucleoside diphosphate kinase-B (NDKB) [72]. 
NDKB is also known to be a transcriptional regulator of MYC, a well-known oncogene [73]. 
Phosphohistidine kinases are best characterized in two component histidine kinase systems in 
prokaryotic cells. These systems are also vital in signal transduction, resulting in transcriptional 
activation [59]. Furthermore, both histone H4 and H1 have shown to be targets of PHPT1 in 
vitro [43, 44]. PHPT1 has been shown to dephosphorylate H4 and have phospholysine activity 
to dephosphorylate H1 in vitro. PHPT1-mediated histone dephosphorylation has potential to 
widely influence protein expression. It is well known that transcription can be mediated through 
a plethora of histone modifications. However, the impact of these modifications and full 
characterization of PHPT1 regulation has not been elucidated.  
Proteomics & alcoholic liver disease 
 As previously mentioned, ALD can develop in many ways, and monitoring its 
progression in a patient and a model is difficult. To properly investigate the onset of this 
disease, as well as elucidate pathways involved that have yet to be discovered, it is necessary 
to use an approach that will both, provide information about known disease states, and 
unbiased information for discovering novel players. A key indicator of cellular functions and 
disease state is protein expression levels. Protein expression data provides a snapshot of the 
genes that have been activated, as well as PTMs that may be influencing activation. These data 
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differ from genetic information, such as DNA or mRNA, that only show the potential expression 
profile. In the case of ALD, the expression levels of key proteins such as epoxide hydrolase 
(EPHX1) and cytochrome P450’s (CYP2E1) are critical indicators for onset of hepatosteatosis 
[24]. Other proteins such as the PPAR family (α, β, and γ), the LXR or RXR proteins, or 
inflammatory proteins like cytokines or JAK/STATS, provide critical information about the 
severity of the disease and the mechanism of onset. Therefore, to thoroughly study this disease, 
we must be able to identify these proteins and their abundances in an accurate and 
reproducible manner. However, to elucidate new mechanisms involved in disease progression, 
our approach must also remain unbiased toward known targets. To obtain measurable and 
reproducible unbiased data regarding the global proteome expression levels, we will utilize 
mass spectrometry-based proteomics techniques. Specifically, shotgun proteomics using data-
dependent acquisition, followed by label free quantification of purified tryptic peptides from 
samples lysates, to determine significant protein expression changes between treatments. 
Mass spectrometry and proteomics.  
 Initial proteomic studies involved 2D separation gels, which would discriminate proteins 
based on their molecular weight on one axis and the isoelectric point on another axis. This 
technique allowed sufficient separation of proteins in a lysate to determine expression difference 
of a single protein or protein group between treatments. It would then be required to determine 
the identity of each protein recognized as differentially expressed. This process could be done 
by extracting the protein or protein group, purifying, and performing an NMR or mass 
spectrometry analysis of each. This method was tedious and highly objective in determining 
which protein groups differed between treatments. Given the recent advances in mass 
spectrometry, and the ability to pair with separation methods, such as liquid or gas 
chromatography, mass spectrometry-based proteomics has now become a highly accurate, 
high-throughput method.  
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 Advances in instrumentation have enabled the use of mass spectrometry to investigate 
molecules faster and of varied sizes and complexities. Both time-of-flight (TOF) and Orbitrap 
instruments have provided significant advances in resolving power, resolution, and mass 
accuracy of multiple charged ions, such as peptides and proteins. These advances in detection 
methods are paired with the creation of hybrid instruments which allow more accurate 
quantification with less interference from neutral molecules or undesired ions. Hybrid 
instruments incorporate a multi-stage system that maximizes ion detection efficiency using ion 
optics to focus and normalize ion beams and velocity, followed by multi-pole (quadrupoles and 
octupoles) stages, which create mass and ion filters and further stabilized ion beams, prior to 
entering main or secondary detection components. The addition of a linear ion trap can allow 
simultaneous MS/MS filtration and detection, while the primary detector such as an Orbitrap is 
performing full-scan detections. MS/MS has also been improved for proteomic purposes. There 
now exists a plethora of MS/MS dissociation techniques that can break specific bonds of the 
investigators choice. Additionally, MS/MS is no longer limited to MS2, and multiple instruments 
can perform MSn where n is limited typically by the abundance of the molecule being 
investigated. The advancements in instrument ionization methods also enhanced mass 
spectrometry-based proteomics. Specifically, the development of electrospray ionization (ESI), 
paired with liquid chromatography, and matrix assisted laser desorption/ionization (MALDI), 
make it possible for relatively easy ionization of complex protein samples for mass spectrometry 
analysis. Continuing advances in instrumentation and ionization methods are making mass 
spectrometry-based proteomics a highly accessible field. 
 Another key aspect that has allowed mass-spectrometry to become the go-to method for 
proteomic analysis is the pairing with liquid chromatography [74]. Liquid chromatographs (LC) 
use pumps and filtered columns to create separation of a sample on the molecular level, 
creating a stable and reproducible gradient of molecular influx in-line with the mass 
spectrometer. This technique is performed using sold phase and liquid phase separation. In the 
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case with proteomic studies, the liquid phases are an aqueous buffer (hydrophilic) and an 
organic buffer (hydrophobic). The solid phase is usually carbon chains of specified length and 
density which bind to the proteins/ peptides present in a complex sample. Peptides that are 
highly polar and most soluble in the aqueous phase will not bind to the solid phase (column) and 
be the first to flow through in a reverse phase column set-up. Coinciding with MS detection, the 
LC will increase the ratio of organic: aqueous liquid phase, creating a gradient. This gradient will 
allow increasingly polar peptides to solubilize and release from the column for mass 
spectrometry identification. In-line LC allows for stable peptide influx, preventing the instrument 
from being overwhelmed with numerous peptides simultaneously, and provides a reproducible 
polarity-based gradient for reference. Liquid chromatography, paired with an ESI source, has 
made it possible to analyze a complex protein mixture efficiently and accurately. Advancements 
in liquid chromatography, including high-pressure and ultra-high pressure (HPLC and UHPLC) 
systems, have allowed for even more efficient separation of peptides and higher degrees of 
reproducibility in liquid chromatography-paired mass spectrometry (LC-MS).  
 Numerous advancements in mass spectrometry have made it the ideal instrument for 
proteomics studies. In our studies, we will be utilizing LC-MS for label free quantification of cell 
lysates, individual proteins, and animal tissue lysates. This method will allow us to identify and 
quantify proteins present in these tissues in a reproducible and accurate manner. The primary 
instrument utilized will be a hybrid quadrupole-Orbitrap instrument (Q-Exactive Plus, Thermo), 
using a top 10 data-dependent acquisition method. Further information on the exact 
specifications of this instrumentation will be included in the respective methods sections. 
Label free quantitation 
 The process of protein quantification begins with the sample preparation immediately 
following protein purification. Following lysis and protein purification, protein concentrations are 
determined from each sample and standardized across all samples being analyzed. For our 
studies standard protein quantities (between 100-200 µg) are then added to filter-aided sample 
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preparation (FASP) columns to undergo buffer exchange and trypsin digestion, as described 
previously [75]. The purpose of the buffer exchange is to remove the detergents, which were 
used for lysis, that cause interference with LC/MS analyses. This exchange is accomplished 
using 8M urea as a wash buffer to keep the proteins solubilized. Then, all proteins are reduced 
to break disulfide bonds and immediately alkylated to prevent unwanted reactivity of free thiol 
groups. These modifications assure that all proteins are denatured and help insure the complete 
digestion by trypsin. Following modifications, another buffer exchange takes place to allow for 
trypsin function in ammonium bicarbonate. Trypsin digestion occurs at 37° C overnight, creating 
peptides that are either lysine or arginine-terminated. This digestion also allows the peptides to 
now flow through the filter. Peptides then must undergo a desalt procedure. Salt analytes 
interfere with ionization efficiency and can create adducts that change peptide masses and 
interfere with quantification. The desalt procedure is concluded with elution by acetonitrile, 
which is then placed under a vacuum until dryness. Samples are resuspended in 0.1% formic 
acid in water at a concentration of 1-5 µg/µl. There are a variety of other sample processing 
methods available including, in-solution and in-gel digestions, but most methods apply the same 
chemical manipulations of reducing, alkylating, and digesting proteins to produce purified 
peptides in a slightly acidic solution.  
 Samples then undergo LC-MS analyses consecutively, using the same procedure, 
column, and ESI tip for each sample to ensure reproducibility. Instrumental standards are run 
before and after samples for quality assurance. Samples are run with either technical or 
biological replicates as well. LC-MS analysis provides qualitative information of individual 
peptide masses, as well as quantitative information of peak intensities relative to the noise level. 
In addition, MS/MS data provides peptide backbone information that can be used to identify 
specific amino acids and modification on each peptide. This information is then searched 
against the known proteome database to match the identified peptide peaks in the MS data with 
known proteins.  
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 In our studies database peptide identification is performed using the MaxQuant 
(maxquant.org) search algorithm to determine peptide identifications and quantity. Peptide IDs 
are determined using a 0.01% false discovery rate to guarantee accurate protein recognition. 
This algorithm quantifies the protein abundances by converting the relative peptide intensities 
originating from the same protein into label free quantification intensities. This calculation is 
done following peptide identification across all samples and replicates. The algorithm then 
assumes most protein abundances should remain constant across all samples, regardless of 
treatment type. In addition, the algorithm considers the number of peptides (unique and 
repeated) identified that relate to each protein, as well the total intensity of all the peptides from 
the same protein.  Using these factors, MaxQuant creates a label free quantification (LFQ) 
intensity which is then used for quantification, in lieu of the absolute intensity of each peptide 
provided by the LC-MS raw data. LFQ peptide count cut-offs are set to 1 to minimize lost 
intensities with a majority of the calculated LFQ intensities being within a few percent of the 
absolute intensity values. The LFQ values are then used to compare control and treatment 
samples and to determine significant differentially expressed proteins. Label free quantitation 
has been shown to be a reliable method for comparing protein expression from multiple 
samples to each other [76]. To further strengthen the confidence in the LFQ method, the use of 
multiple (n≥3) technical or biological replicates is necessary. 
Proteomic studies using animal models  
 The primary animal model used in these studies has been Mus musculus. The mouse 
model provides more biological relevance than mouse or human cells alone. The homogeneity 
between mice and human organ functions and systems, combined with their short lifespan and 
quick reproductive cycle, make them an ideal candidate. Mouse models of alcoholism have also 
already been well developed and characterized [77, 78]. The primary mouse strain we used was 
the C57BL6/J mouse which has been widely used in the 10-day chronic ethanol plus binge 
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model. This model has been shown to induce severe hepatosteatosis apparent by the 
development of lipid droplets and inflammation [77].  
 Further validation of this model and the disease state is accomplished through mass 
spectrometry-based proteomics. Proteome-wide LFQ quantification of differentially expressed 
proteins between the treatment and controls groups will identify proteins significantly changed 
during disease onset. This method has been validated against known proteome changes such 
as increase in expression of CYP2E1 and EPHX1 [24], as well as other indicators of 
hepatosteatosis [77]. Using proteomics in combination with an organism physiologically similar 
to humans allows us a more accurate depiction of the disease state and cellular components 
being influenced.   
 The other advantage of using a mouse model for proteomic disease analysis is that 
proteome database for Mus musculus is available and well-annotated. This database is used to 
identify the proteins discovered from mass spectrometry-detected peptides. A well-annotated 
database is important to have in that it will provide more complete information about the proteins 
identified rather than an abundance of uncharacterized proteins. The primary database used for 
the mouse model searches is extracted from UniProt (uniprot.org) and updated regularly to 
incorporate all recent annotations. These annotations are of additional importance following 
identification and quantification, as they are used for mechanistic analyses as well. The 
similarity of human and mouse cellular functions and pathways allows the protein expression 
information to be employed for determining upstream and downstream regulators influenced by 
the identified differentially expressed proteins. This analysis is a key step in elucidating novel 
enzymes and mechanisms involved in the disease being investigated. 
Significance of protein modification in alcoholic liver disease 
 Post-translational modifications can influence all aspects of protein function. There is a 
plethora of modifications that can occur on an individual protein causing biochemical changes in 
the proteins conformation. These modifications can directly impact protein function or 
21 
 
expression, or indirectly impact a protein affecting its downstream targets or upstream 
regulators. Ethanol can induce a wide variety of modifications through a direct manor with the 
creation of ROS or an indirect manner through signaling mechanisms brought on by its 
presence. Ethanol can lead to the creation of ROS such as acetaldehyde, hydrogen peroxide, 
and free radicals. These are known to oxidize susceptible amino acid residues, such as 
methionine, which often leads to loss of function [79]. This inhibition is observed in  calmodulin 
and interferon kappa B alpha, as well as other proteins [80-82]. Other modifications such as 
phosphorylation, acetylation, and methylation are induced by ethanol as well. These 
modifications are induced by the change in metabolism and cell signaling brought on by ethanol, 
and they will further influence cellular function and protein expression.  
 Oxidative modification is the most prevalent PTM directly induced by ethanol [83]. 
Oxidation is notorious for causing loss of function and disturbing vital cellular functions [79]. The 
presence of ROS is contested directly by anti-oxidants and hydroxylation enzymes such as 
glutathione and epoxide hydroxylase [22, 84]. The role of these molecules is to hydrolyze the 
oxidants preventing them from directly impacting vital proteins. In binge and acute models of 
ethanol exposure, the presence of these molecules is initially decreased as they are 
overwhelmed by the abundance of ROS present. However, in chronic models, the cell responds 
to continual ethanol exposure by overexpressing oxidant scavengers such as EPHX1 [24]. Once 
depleted, however, antioxidants initially present in the cell take time for replenishment, leaving 
the cells more susceptible to ethanol-induced oxidative damage.  
 Other modifications are impacted as well following chronic ethanol exposure. A 
consistent increase in ethanol metabolism will change the ratio of molecules involved in 
glycolysis and the citric acid cycle. Ethanol must be metabolized by alcohol dehydrogenase and 
then further by aldehyde dehydrogenase to prevent the presence of acetaldehyde [15].  This 
reaction results in an increase of NADH molecules which can inhibit the activity of the citric acid 
cycle. This stall will cause an increase in citrate in the mitochondria, which gets converted back 
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into acetyl-CoA in the cytoplasm via ACL. An increase in the acetyl-CoA pool directly correlates 
to acetylation of proteins, including histones, which will directly result in expression changes 
[85]. Furthermore, abundance of acetyl-CoA can also dysregulate glycolysis and activate 
alternative pathways for cellular metabolism. This effect leads to greater protein modifications 
occurring, such as methylation, phosphorylation, and the previously mentioned oxidation and 
acetylation [85]. Even minor changes in PTM’s of regulatory proteins like histones or MAP-
kinases will result in massive expression alterations [86]. Continuous ethanol exposure in a 
chronic model will lead to irreversible expression changes via PTM’s and result in the 
development of severe ALD [13].   
Summary of approaches and project aims 
 The adverse effects of alcoholism on the human liver are well known. Chronic ethanol 
consumption is strongly correlated to a unique pathology of liver diseases known as ALD. The 
mechanisms and players involved in the onset and progression of this disease are still poorly 
understood. Many of the proteins believed to be key regulators have been identified through 
mRNA characterization or biased approaches targeted at individual proteins. Our study aimed to 
identify and characterize a novel player in the onset of ALD through the global proteomic 
analysis of an ethanol-induced hepatic steatosis models. An acute model study using HepG2, 
hepatocyte-like cells, was performed and characterized using the SILAC approach to determine 
expression and modification changes. This study identified a phosphohistidine phosphatase 
(PHPT1) as being selectively oxidized but showed no change in expression levels following the 
acute exposure. Further characterization of this modification and its influence on PHPT1 was 
performed using mass-spectrometry based modification site mapping and a novel 
phosphohistidine phosphatase assay.  
 In addition, a 10-day chronic plus binge mouse model was used to determine more 
biologically relevant effects of long-term chronic ethanol exposure on the development of liver 
injury. Following a global proteome characterization between ethanol and control diet-fed mice 
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using high-resolution mass spectrometry, we identified PHPT1 as being significantly 
downregulated by ethanol exposure. This discovery created the basis for the second and third 
aim in determining the significance of PHPT1 expression prior to and following ethanol-induced 
hepatic steatosis. To investigate this, we developed both a liver-specific overexpression model 
and bred an organism-wide knockout model. Overexpression was accomplished using an 
adenoviral-based vector delivery of PHPT1 paired with a liver-specific albumin promotor 
administered intravenously through the tail. This yielded a significant increase in PHPT1 
expression specifically in the liver, which lasted for multiple weeks. In addition, we requested 
creation of a non-conditional PHPT1 knockout mouse through cre-mediated lacZ substation by 
UC Davis. The heterozygous genotype yielded an average of 50% mRNA and protein 
expression, compared to wild-type, in all tissues tested but displayed no obvious phenotypic 
changes. All heterozygous crosses, however, did not yield a complete PHPT1 knockout 
offspring. This result suggests that PHPT1 is critical for early development. Both models where 
then characterized using mass spectrometry-based phenotypic characterization to determine 
the mechanisms impacted by PHPT1 expression alteration.  
 Finally, both models were used in the 10-day chronic plus binge ethanol exposure model 
to determine the influence of PHPT1 on the development of ethanol-induced hepatic steatosis. 
Groups were pair-fed with a control (sucrose supplemented) or ethanol diet. Disease 
progression was determined using liver sectioning histology and circulating aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and triglyceride (TAG) levels. PHPT1 
expression levels were determined using western blot and LFQ values from global proteomic 
analyses. Finally, mass spectrometry-based phenotypic characterization was performed on liver 
tissue from each mouse. This method was used to identify mechanisms and pathways 
influenced by PHPT1 during chronic ethanol exposure. Conclusions of these studies provide 
greater insight into the role PHPT1 and phosphohistidine signaling plays in the onset of ethanol-
induced hepatic steatosis and potential contribution to the pathogenesis of ALD. 
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Chapter 2: Structural and activity characterization of human PHPT1 after oxidative 
modification 
Summary 
 The structure and primary function of PHPT1 has been recently elucidated (Chapter 1 
section) [57, 62]. However, the biological influence of PHPT1 phosphatase activity on cellular 
functions and vice-versa are not fully understood. The number of confirmed targets of PHPT1 
remain minute in comparison to the estimated 6% of the protein phosphorylation being 
attributed by histidine phosphorylation [87]. Furthermore, the influence of post-translational 
modifications (PTMS) such as phosphorylation or oxidation on PHPT1 have not been 
investigated. Currently, only one PTM has been identified on PHPT1 and that modification, 
being constitutive N-terminal acetylation [64], is the most common modification in eukaryotic 
proteins [88]. The role of PHPT1 and how PTMs influence its activity and structure is necessary 
to further characterize the significance of this protein. Specifically, we wanted to determine how 
ethanol-induced PTMs influenced PHPT1 phosphatase activity givens its regulation of ATP- 
citrate lyase, a key protein in ethanol metabolism. This study was conducted by first creating an 
acute ethanol exposure model with HepG2 cells, exposing them to high amounts of ethanol for 
8-12 hours. This exposure led us to identify PHPT1 as a target of increased oxidation following 
ethanol exposure. This acute exposure was recreated in vitro using the known reactive oxygen 
species (ROS) hydrogen peroxide.  Following treatment, we used mass spectrometry-based 
modification site mapping to determine the exact location and quantify the percent of oxidized 
PHPT1. For activity characterization, we used oxidized and non-oxidized PHPT1 in a mass 
spectrometry-based phosphohistidine phosphatase assay and explicit solvent molecular 
dynamics using computer simulations of the known PHPT1 structure with and without the 
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oxidative modification. Our investigation found that PHPT1 can be selectively oxidized on Met95 
located in the substrate binding region; however, the oxidation does not limit PHPT1 
phosphohistidine phosphatase activity in vitro. This result suggested PHPT1 plays a more 
complex role in ROS-mediated cellular response. 
Introduction 
Ethanol-induced reactive oxygen species 
 A large influx of reactive oxygen species (ROS) are present in hepatocyte cells following 
acute and chronic ethanol exposure models. These ROS are generated both directly and 
indirectly by ethanol metabolism. Ethanol leads directly to the generation of hydrogen peroxide 
and acetaldehyde consequentially of ethanol’s metabolism. Acetaldehyde is directly created by 
alcohol dehydrogenase and hydrogen peroxide, which can result from the natural 
decomposition of ethanol in an intercellular environment [18]. Furthermore, both molecules can 
lead to the creation of free radicals such as a superoxide radical and reactive nitrogen species 
like peroxynitrite. This influx of radicals exacerbates the amount of ROS present in the cell. In 
an acute model, oxidation is most likely to occur more readily due to the cell not having the 
opportunity to increase expression levels of protective antioxidant, or hydroxylase enzymes, and 
decrease the production of acetaldehyde via alcohol dehydrogenase [89]. In chronic exposure 
models, ethanol metabolism is primarily performed by CYP2E1 as a consequence of alcohol 
dehydrogenase inhibition due to an increase in NADH and acetaldehyde [90]. Additionally, 
overexpression of protective hydroxylase enzymes occurs to reverse the effects of ROS [91]. 
HepG2 cells 
 HepG2 cells were derived from a  a fifteen-year-old caucasian American male with well 
differentiated hepatocellular carcinoma. The cells resemble immortalized human hepatocytes 
and can be used to simulate liver experiments. HepG2 cells have been used previously to 
investigate the liver metabolism of toxic reagents including ethanol [92]. However, given the 
absence of expression of CYP2E1 and ADH1, these cell are not the ideal model for studying 
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oxidative stress. Similar to hepatocytes, HepG2 cells express high amounts of albumin and 
transferrin.  
Oxidation modification 
 Oxidation modifications have been observed in a wide variety of proteins. This oxidative 
modification can occur on methionine, tyrosine, tryptophan, or cysteine residues and can occur 
as single, di- or tri-oxidation in some situations. An increase in the presence of ROS can lead to 
an increase in global protein oxidation. These oxidants can lead directly to protein oxidation by 
interacting with a susceptible residue or can increase oxidation indirectly by saturating 
glutathione, and increasing CYP2E1 production in cells exposed to ROS over long periods of 
time [89]. CYP2E1 activation leads to an increase in expression and results in the creation of 
more NADP+. Reduction of NADP+ to NADPH leads directly to more ROS present in the cell. 
Protein oxidation, especially on methionine residues, leads to inhibition of enzymatic function in 
the well documented case of calmodulin and interferon kappa B alpha [81, 82, 93]. The 
exception to this is with glutathione-S-transferase, which can be oxidized on multiple methionine 
residues without any influence in activity [84]. PHPT1 has two methionine residues as potential 
targets of oxidation (Met64 and Met95) and multiple other residues susceptible to oxidation 
(cysteine, tryptophan, and tyrosine) as well. One methionine residue occupies the middle of the 
substrate binding region of PHPT1 (Met95) and has been shown to be directly involved in 
substrate binding region stability [62]. Due to the susceptibility of this residue to oxidation, its 
importance in substrate binding, and the nature of the oxidative modification, we hypothesize 
that if PHPT1 oxidation is selectively occurring at this residue, and PHPT1 phosphatase activity 
will decrease as a result of oxidative modification.   
Phosphohistidine phosphatase assay 
 Phosphohistidine is known to be an unstable modification in vitro. Therefore, the 
development of a reliable phosphohistidine phosphatase assay is not trivial. Currently, the only 
phosphohistidine phosphatase assays that have been used rely on phosphohistidine analogs 
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that are more stable during the experiment. The benefit in stability, however, is accompanied 
with a decrease in specificity. This compromise makes the assay less reliable when comparing 
to in vivo results. Another phosphohistidine phosphatase assay developed relies on a malchite 
green reporter molecule that is activated by the removed phosphatase group [48]. This method 
requires the reaction to take place completely. This requirement makes it an indirect 
measurement and does not allow reaction monitoring in real-time. We will aim to develop a 
mass spectrometry-based assay utilizing a small histidine-phosphorylated peptide, which can be 
identified and verified using MS/MS. In addition, the reaction can be monitored in real-time and 
take place during direct infusion so any changes in phosphorylation can be seen immediately 
following enzymatic activity. This novel assay will look directly at the phosphorylated and non-
phosphorylated peptides and can be used to quantify the amount of each present in the sample 
at each time point. 
Modification site mapping 
 Post translational modifications are a wide variety of chemical additions than can occur 
on many different amino acids. They can influence activity, signaling, and even protein 
longevity. Mass spectrometry is a valuable tool used to identify these modifications. Using full 
scan analysis of trypsin-digested peptides, modified peptides can be identified by a mass shift 
equivalent to the added modification. This measurement will allow identification of the modified 
peptides and what modification is present. To determine the location of this modification a 
second scan is employed following fragmentation. This MS/MS scan takes place after a specific 
(modified) peptide has been selected for isolation. Following isolation, the peptide undergoes 
fragmentation such as collision induced dissociation (CID), which will break the peptide bonds. 
This fragmentation method results in neutral losses of individual amino acid from the parent 
peptide. The resulted peptide fragment masses will be seen in the MS/MS scan showing C-
terminal retaining Y ions and N-terminal retaining B-ions.  The amino acid which contains the 
modification will display a mass shift equal to that of the modification at the respective B or Y ion 
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location. This method will allow us to determine the exact location of the modification. Finally, 
this peptide can be quantified using the area-under-the-curve created by the intensity of the 
peptide signal over the time the signal was present. This quantification method will allow us to 
compare relative abundance of modified peptides to non-modified peptides.  
Materials and methods 
Stable isotope labelling in cell culture 
 Stable isotope labelling in cell culture (SILAC) was performed as previously described 
[94] on HepG2 cells in a preliminary study by a previous member of the lab. In brief, heavy L-
arginine (R) (13C6, 15N4) and L-lysine (L) (13C6, 15N2) isotopes (Sigma Aldrich) were 
supplemented into R&L depleted Dulbecco’s modified eagle medium. HepG2 cells were 
cultured in either the heavy labelled medium or normal medium (light labels) to integrate the 
labels into the proteome. Following multiple passages heavy labelled cells were treated with 200 
mM ethanol for 4-hours. Control samples were treated with PBS. All cells were collected 
following the 4-hour treatment. Cells were lysed with 2% SDS and following protein isolation and 
quantification samples were mixed at a 1:1 heavy: light protein concentration ratio. Samples 
were prepared using the filter-aided sample preparation method followed by desalting on a C18 
column and placed under vacuum until dry.  
Western blot analysis 
 Western blot analysis was performed as previously described by Bell-Temin et al. [94]. 
In brief, proteins were separated by SDS-PAGE and transferred to nitrocellulose. S Ponceau 
stain was used to confirm complete transfer. Blocking was performed with 5% dry milk in PBS 
containing 0.1% Tween 20. The blot was incubated in the primary antibody overnight at 4° C 
with rabbit polyclonal anti-PHPT1 (SC-130229, Santa Cruz). PHPT1 primary antibody binding 
was detected by incubation with goat anti-rabbit secondary (1:10000, Cell Signaling 
Technology) and activation by picomolar sensitive chemiluminescent reagents (Pierce). Images 
were developed on film and quantified using densitometry with Image J. Intensity’s were 
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normalized against GAPDH with a rabbit polyclonal anti-GAPDH antibody (1:5000, Cell 
Signaling Technology) following stripping and reprobing. 
Results and discussion 
 The initial study with HepG2 cells showed a two-fold increase in PHPT1 oxidation 
following acute ethanol exposure compared to the control samples that were untreated. The 
western blot analysis revealed that this occurred independent of expression change as PHPT1 
abundance was the same after 4-hour ethanol exposure (Figure 5). To verify the ethanol-
mediated targeted oxidation of PHPT1, we performed modification site mapping using human 
recombinant PHPT1 (hPHPT1) to determine if targeted oxidation of PHPT1 was taking place 
following ROS exposure. Furthermore, we determined the influence of this modification on the 
phosphatase activity of PHPT1 using a novel mass spectrometry-based phosphohistidine 
phosphatase assay, a colorimetric phosphatase assay, and explicit solvent molecular dynamic 
simulations. The remaining results are contained in previously published work [65] and are 
contained in Appendices A and B. This article has been reproduced with the consent of the 
publisher (Appendix C).  
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Chapter 3: Development and characterization of phosphohistidine phosphatase 1 
knockout and overexpression models in Mus musculus. 
 
Summary 
 Phosphohistidine modification and signaling in mammalian models has not been well 
characterized despite its importance in other cell types in mechanisms such as two component 
histidine kinase signaling in bacterial models [59]. The presence of a known phosphohistidine-
specific phosphatase in mammals, PHPT1, further suggests phosphohistidine plays a crucial 
role in cellular functions. In this study, we use two methods to create a PHPT1 overexpression 
and knockout model for further understanding phosphohistidine signaling. The overexpression 
method employs an adenoviral-based construct for liver-specific overexpression, and the 
knockout was achieved using cre recombinant-based gene recombination. Furthermore, these 
models were both characterized using high resolution mass spectrometry-based proteomics to 
further validate the models and provide insight into the influence of phosphohistidine signaling 
manipulation. These models allowed us to identify PHPT1 as embryonically lethal and 
determine novel key regulators influenced by its expression. Implementation of these models in 
future studies will lead to further insight into the role of phosphohistidine signaling and PHPT1 
regulation in mammalian cells. 
Introduction 
 Phosphohistidine phosphatase (PHPT1) was discovered in porcine liver in 2002[41]. 
PHPT1 shows phosphatase activity toward phosphohistidine residues in vivo and can catalyze 
the dephosphorylation of phosphoramidate [43] and phospholysine [44] in vitro. PHPT1 has only 
a few known targets include KCa3.1 calcium ion channel [39], ATP-citrate lyase [35], and G-
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protein (β subunit) [37]. Given the robustness of phosphohistidine modifications predicted to 
occur in mammalian cells it is likely that there are many other targets of PHPT1 yet to be 
elucidated [87]. Additionally, the effect of PHPT1 expression on cellular function in vivo has yet 
to be fully understood. Studies investigating the effects of PHPT1 knockdown have been 
performed in a few different cell types. In pancreatic β cells and neuronal cells, PHPT1 has 
been shown to influence important pathways, such as insulin secretion and cell proliferation, 
respectively [45, 46]. PHPT1 overexpression has also been performed on cancer cell lines, 
showing PHPT1 plays a role in cell migration and possibly epithelial-mesenchymal transition 
(EMT) [51, 66]. These studies show that PHPT1 expression has influence on critical cellular 
pathways throughout the mammalian system. PHPT1 expression is shown to be most elevated 
in heart, spleen, liver, muscle, and brain tissues [41, 95]. PHPT1 is also part of the Janus family 
of proteins according to the family domain classification available on the Universal Protein 
Resource (uniport.org), which are best characterized in Drosophila melanogaster and involved 
in sex differentiation during development [49]. It is the only known phosphohistidine 
phosphatase to be a part of this family of proteins.  
 PHPT1 targets phosphorylated histidine residues for removal of the phosphate group 
from the amino acid [41]. Phosphohistidine is also not well characterized. The modification is 
best known for its acid labile nature [56], which makes it more difficult to study than the well 
characterized phospho- serine, threonine, and tyrosine residues [96]. Phosphohistidine can take 
place at the N-1 or N-3 on the imidazole side chain [36]. The N-1 modification is generally less 
stable and most often occurs as an intermediate on phosphatase or kinase enzymes during 
phosphate group transfer between ATP and the substrate [97]. Histidine residue on these 
enzymes are often the catalytic amino acid, which is the case for H53 in PHTP1 [62] as well. 
The N-3 modification is associated with long-term phosphorylation and requires a kinase and 
phosphatase for addition and removal [87]. Targets of this kind of phosphohistidine modification 
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include those of PHPT1 as well as histone H4 (which is shown to be a target of PHPT1 in vitro 
but not in vivo) [38, 43].  
 Despite the lack of knowledge currently on phosphohistidine signaling in mammals, it is 
still estimated that 6% of protein phosphorylation occurring are phosphohistidine modifications 
[87]. This modification has been shown in well characterized species and mammals to cause 
activation/inhibition and influence signaling of molecules. Therefore, PHPT1, a phosphohistidine 
specific phosphatase, is likely a key player in many pathways via phosphohistidine regulation. 
Canonical pathways regulated by phosphohistidine can be elucidated using PHPT1 expression 
manipulation followed by proteomic analysis. Using an in vivo mouse model will provide a model 
with high translational potential due to similarity with the human proteome. Furthermore, 
characterization of the PHPT1 expression in a large vital organ such as the liver will provide 
ease in targeting, large quantity of tissue available per animal, and insight into consequences of 
influencing liver regulatory pathways, which are key for the entire organ system function.   
 Expression manipulation has been achieved in two ways. Overexpression of PHPT1 was 
assessed using a tail-vein injection method of adenoviral vectors encoding for PHPT1 and 
enhanced green fluorescent protein (eGFP) control viruses with an albumin promoter (for liver 
specificity). This method has been previously described in Wilson et al [98]. Adenoviral vectors 
were obtained and constructed by Vector Biolabs (Pennsylvania). To create the knockout 
model, male and female C57BL/6J PHPT1tm1.1(KOMP)Vlcg heterozygous(het) mice were 
created by the KOMP repository at University of California (UC) Davis through cre-mediated 
deletion with a LacZ gene substitution. These mice were obtained at 4-6 weeks old and were 
cross bred with C57BL/6J wild-type mice to confirm fertility and for colony establishment. 
Characterization was performed using discovery-based proteomics, allowing us to take a 
snapshot of proteomic changes induced by PHPT1 expression alteration. With this study, we 
hope to further understand the role PHPT1 plays in cellular regulation in vivo. 
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Materials and methods 
Adenovirus animal models 
 Male C57BL/6J mice were obtained from the Jackson Laboratory and fed a standard 
rodent chow and water ad libitum, whilst maintained on a 12h light and dark cycle. Adenoviral 
vectors encoding for PHPT1 and eGFP control viruses with an albumin promoter (for liver 
specificity) were obtained and constructed by Vector Biolabs (Pennsylvania). Mice were injected 
with 1X109 plaque-forming units (pfu) of adenovirus via tail vein at 10-12 weeks of age. Mice 
were sacrificed 5 days later for gene expression analysis. All animal studies were performed in 
compliance with IACUC approved protocols by the University of South Florida. 
Cre recombinant animal models 
 Male and female C57BL/6J PHPT1tm1.1(KOMP)Vlcg heterozygous mice were created 
by the KOMP repository at University of California (UC) Davis through cre-mediated deletion 
with a LacZ gene substitution. These mice were obtained at 4-6 weeks old and were cross bred 
with C57BL/6J wild-type mice to confirm fertility and for colony establishment. Tail snips were 
obtained for genotype verification. Mice were sacrificed at 15 weeks old and multiple tissues 
were obtained and immediately snap frozen in liquid nitrogen for preservation to be used for 
phenotyping and characterization.  
Genotyping 
 Tail snips were obtained from mice less than 21 days old for DNA extraction. DNA 
purification was performed using the GeneJET genomic DNA purification Kit (K0722, Thermo 
Scientific) according to the manufacturer’s instructions. PCR primers for both the PHPT1 and 
LacZ+ gene were provided by UC Davis, and PCR’s were performed using a PTC-200 thermo 
cycler (MJ Research) at UC Davis specified parameters. DNA separation was carried out on a 
1% agarose gel in Tris Borate EDTA (TBE) buffer (Thermo Scientific) with 0.1% ethidium 
bromide. Visualization was completed using the LICoR AI600 instrument with UV light exposure 
of less than 0.5 sec.  
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Phenotyping 
 PHPT1 expression levels were determined using western blot analyses of various tissue 
types. Tissues were homogenized in a 125 mM Tris buffer with protease and phosphatase 
inhibitors on ice. Protein extraction was performed in a 4% SDS buffer at 95° C followed by 
sonication and centrifugation for protein purification. Protein quantification was performed using 
the Pierce 660 nm protein assay solution (Thermo Scientific) supplemented with an ionic 
detergent compatibility reagent (Thermo Scientific) on a 96 well plate. Three technical replicates 
were used for each sample and two for each BSA standard. Western blot analysis was carried 
out using TGX any KD gels (Bio-Rad) followed by a semi-dry transfer to either nitrocellulose or 
PVDF membranes. Nitrocellulose membranes were Ponceau stained immediately following 
transfer for confirmation of equivalent loaded total protein. PHPT1 was probed for using a 1:500 
dilution in 5% BSA of the N-23 anti-PHPT1 antibody (SC-130229, Santa Cruz). A 1:5000 dilution 
in milk of the HRP conjugated goat anti-rabbit secondary (Cell Signaling Technology) was used. 
Development was carried out using SuperSignal chemiluminescent reagent (Thermo Scientific) 
and signal intensity was measured on the AI600 (LICoR) instrument. Loading control was 
carried out using either a 1:2000 dilution of anti-GAPDH (Cell Signaling Technology), or 1:1000 
dilution of anti-β-actin (Cell signaling technology), depending on the tissue type, and a 1:5000 
dilution in milk of an HRP conjugated rabbit anti-mouse secondary (Cell Signaling Technology).  
 Further quantification analysis was performed using an eGFP ELISA kit (Abcam, 
ab171581). The procedures were followed according to the manufacturer, in brief, standards 
were created in technical duplicates and samples in technical triplicates and PBS was used for 
the blank. Wells contained 100 µl of either samples or standard as well as 10 µl of the balance 
solution and 50 µl of the conjugate solution. Plate was mixed for 1 hour at 37° C. Following 
washing, 50 µl of substrate A and B were added to each well and incubated for another 15 min 
at 37°C. The reaction was halted with 50 µl of Stop solution and read on a microplate reader 
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(Versa Max, Molecular Devices) at 495 nm. Results were calculated using SoftMax Pro software 
(version 5.4.1) based on a 4-parameter logistic standard curve fit.  
Mass spectrometry-based phenotypic characterization 
 Following protein extraction from liver tissues, 150 µg of protein from tissue lysates were 
prepared for mass spectrometry analysis using the filter aided sample preparation (FASP) 
method previously described [75]. In brief, samples were placed on a 30kDa filter spin column 
(Millipore) and washed with 8 M urea to remove any detergents. Buffer exchange was followed 
by N-terminal alkylation and reduction using Idoacetamide and DTT respectively. Samples were 
then trypsin/Lyc-C digested (Promega) overnight at 37° C and eluted with 50mM Ammonium 
bicarbonate and 0.5 M sodium chloride. Samples were then desalted using a Sep-Pak C18 
desalt columns (Waters). Following centrifugation under vacuum until dryness, samples were 
resuspended in 0.1% formic acid for mass spectrometric analysis.  
 Generated peptides were separated using a reversed phase PepMap100 C18, 3 µM, 100 
Å, 75 µM I.D. X 50 cm nanoviper column (Thermo), with a PepMap100 C18, 3 µM, 100 Å, 75 µM 
I.D. X 2 cm cap trap (Thermo), on an Ultimate 3000 (Thermo Fischer) HPLC system over a two-
hour gradient (5-40% acetonitrile in 0.1% formic acid). Mass spectrometric analysis was 
performed by a hybrid quadrupole-Orbitrap instrument (Q-Exactive Plus, Thermo), using a top 
10 data-dependent acquisition method with a dynamic exclusion time of 20 seconds. Full scan 
and MS/MS resolution was 70,000 and 17,500 respectively. High-resolution MS data were then 
searched against the Uniprot mouse proteome database using the MaxQuant (1.6.0.16, 
maxquant.org) search algorithm. Variable mods included phosphorylated serine, threonine, and 
tyrosine, and methionine oxidation. First search peptide tolerance was 20 ppm and the main 
search peptide tolerance was 4.5 ppm. Identifications were accepted at a protein and peptide 
false discovery rate of less than 1% and overall localization probabilities of ≥95% for modified 
peptides.  
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 Normalized protein abundances were organized as label free (LFQ) intensities in the 
protein groups file generated by MaxQuant. Further LFQ statistical filtering was performed using 
Perseus (version 1.6.0.7, http://www.perseus-framework.org/) software to determine significantly 
differentially expressed proteins between treatment groups. Significant protein expression fold 
changes between groups were uploaded to Ingenuity Pathway Analysis (IPA) (Qiagen) for a 
bioinformatic analysis revealing predicted upstream and downstream regulators as well as 
activated/inhibited pathways. IPA results were used for phenotypic characterization of PHPT1 
overexpression and knockout models and key regulators identified were validated by western 
immunoblotting. Liver samples were compared between male PHPT1 and eGFP 
overexpression, with male het and wild-type mice of similar ages.  
Statistical analysis  
 Data are presented as means with error bars representative of ± standard error. 
Statistical significance was determined by an unpaired, two-tailed, Welch modified T-test. 
Microsoft Excel (Office 365, 2012) and Perseus (version 1.6.0.7, http://www.perseus-
framework.org/) were used to perform statistical analyses of PHPT1 and eGFP overexpression 
as well as PHPT1 het and wild-type data. Proteomic dataset filtering utilized a Z-score for each 
protein determined statistically significantly by Welch’s t-test for additional filtering of LFQ data. 
This method has been used previously to produce highly efficient discriminative analysis of LFQ 
data [76].This Z-score for each protein reflects the difference between the fold change of that 
protein and the mean fold change of all proteins, relative to the standard deviation of the 
population [99]. Proteins with a Welch modified t-test value of <0.05 and a │Z-score│>1 were 
deemed significant and uploaded for Ingenuity pathway analysis. 
Results and discussion 
Validation of adenoviral PHPT1 expression in mouse models 
 To study the effects of PHPT1 overexpression in vivo in male C57BL/6J mice adenoviral 
based injections were used. Adenovirus has been shown to specifically target the liver [98]. In 
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addition, an albumin promoter was added to the viral vector to increase liver specificity. This 
methodology is advantageous in that it allowed us to specifically target a single organ in adult 
mice to prevent any adverse effects of PHPT1 expression on development. Mice injected with 
either the PHPT1 or eGFP viral constructs showed liver specific overexpression and no change 
in expression in the spleen or other organs. Western blot of PHPT1 expression showed a 
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significant increase in PHPT1 expression compared to the eGFP mice, 5 days post injection 
(Figure 6a). To further validate this overexpression model and liver specificity eGFP 
translational expression was confirmed using an ELISA kit to measure absolute protein 
expression. EGFP expressing liver samples showed approximately 2 ng/ml of GFP as 
compared to less than 0.1 ng/ml in the PHPT1 liver samples and both spleen samples. 
In the knockout model, phenotypic validation of PHPT1 expression was performed on 
tissues known to highly express PHPT1 in wild-type mice (liver, spleen, muscle, and brain). 
PHPT1 protein expression in the het mice was seen to significantly decrease on average by 
approximately 50% in liver, spleen, muscle, and brain tissues as compared to the wild-type 
(Figure 6b). This result is concurrent with the genotype data in which the het mice contain only 
one of the two alleles for PHPT1 expression. These data suggest that PHPT1 transcription and 
translation are reduced organism wide by 50%. 
Breeding colony development and validation 
 Male and female C57BL/6J mice were genetically modified at the KOMP repository with 
a PHPT1tm1.1(KOMP)Vlcg method. This method created heterozygous mouse with a non-
conditional knock-out lacZ gene. Genotypes of these mice were initially confirmed using tail-snip 
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DNA amplification of PHPT1 and the lacZ recombinant gene through a PCR analysis. The wild-
type mice displayed expression of only the PHPT1 gene, whereas the heterozygous knockout 
(het) showed expression of both the PHPT1 gene and the lacZ reporter gene. These mice were 
bred, and offspring were similarly genotyped to determine the viability of a full PHPT1 knockout. 
Following multiple het-het crosses (n>20) genotyping revealed no post embryonic complete 
PHPT1 knockout mice. This result suggests a full knockout of PHPT1 is dying in-utero. A chi-
square test of the total offspring born from these crosses (N=128) allows us to say with >99% 
probability (2 degrees of freedom), that the het-het crosses do not follow the expected 
Mendelian genetics (Table 1). Possible mechanisms for this lethality were not investigated, 
however, many of the pathways that PHPT1 is known to be associated with could be involved in 
this mechanism.  
Age expression validation of PHPT1 
 After expression validation of PHPT1 models was complete we determined if the 
expression of PHPT1 was dependent on the age of the mouse considering our different model 
validations came from varying age ranges. Liver from 11-18 weeks old mice were extracted 
from both sexes and compared to each other and the 8-10-week-old mice used for the ethanol 
exposure models (Chapter 4). Expression validation was performed using a western blot against 
PHPT1 and a β-actin loading control. There was no significant difference between PHPT1 
expression regardless of age group or sex. Through these results, we were able to conclude 
that age and gender does not influence PHPT1 expression levels.  
PHPT1 animal model characterization 
 Following the creation and validation of our PHPT1 overexpression and knockout 
models, we wanted to further characterize the influence of PHPT1 expression and 
phosphohistidine signaling on liver function. Global proteome levels where measured using 
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high-resolution mass spectrometry from liver extracts from eGFP, PHPT1 overexpression, wild-
type, and Het mice. Mass spectrometry intensities were used to further validate PHPT1 
expression between samples. Data showed a 13-fold increase in PHPT1 expression compared 
to the eGFP mice and a 2-fold increase from the het to the wild-type mice (Figure 6a & b). 
These data coincided with our western blot analysis data used for initial validation.  
Using high-resolution mass spectrometry proteome expression data, we next 
investigated key regulators, pathways, and possible downstream targets influenced by PHPT1 
expression changes. These results were elucidated using the core analysis feature in Ingenuity 
Pathway analysis, which predicts these factors based on experimentally provided expression 
fold-changes. IPA utilizes a z-score algorithm, in which a z-score of greater than 2 or less than -
2 represents activation or inhibition, respectively. The p-value of overlap represents the overlap 
in targets influenced by the regulator or pathway and those identified experimentally as 
significantly changed. A low p-value of overlap represents a key regulator that shares many 
targets influenced by our experimental treatment, in this case PHPT1 expression.  
Bioinformatic analysis of protein expression fold changes revealed both PHPT1 
overexpression and knockout models shared significant overlap of downstream targets with key 
regulators HSD17B7, 17β-estradiol, and MYC (Table2). HSD17B7 is involved in steroid and 
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cholesterol regulation via 17β-estradiol synthesis and 3-ketosteriod reductase function [100]. 
MYC and 17β-estradiol are regulators of cell survival [101] and proliferation [102], respectively, 
and both well-known players in cancer development [103, 104]. Although, both PHPT1 
overexpression and knockout induced expression changes have significant overlap with these 
regulators, it appears they are influencing these processes through unrelated mechanisms. 
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Furthermore, the proteins influenced by each PHPT1 expression state differ greatly. The 
proteins identified as significantly influenced and overlapped with these regulators were unique 
to each PHPT1 condition (outer nodes Figure 7a-d). PHPT1 knockout identified the GnRH 
analog as the unique regulator to be predicted as significantly influenced by expression changes 
(Figure 7e). PHPT1 overexpression did not identify any regulators as significantly influenced (-
2<z-score>2).  
 Furthermore, the overlap with the top 3 canonical pathways of each condition do not 
coincide (Table 2), and there were no pathways identified with significant overlap in both 
conditions. However, the pathways identified in each condition give much insight into possible 
mechanisms being influenced by PHPT1 expression. PHPT1 overexpression changes show 
overlap with three pathways of degradation. The glycogen and S-methyl-5'-thioadenosine 
degradation pathways are often a result in an increase of cell proliferation and transcriptional 
activation [105, 106]. In addition, the degradation of α-tocopherol is in response to an increase 
in antioxidant production [107] and leads to an increase in β-oxidation via the production of α-
carboxyethylhydroxychroman [108]. Alternatively, the heterozygous PHPT1 model has 
significant overlap with two pathways that lead to lymphocyte-mediated apoptosis (Table 2). 
Specifically, in the Nur77 signaling pathway, apoptosis is activated via Nur77 interaction with 
RXRα [109]. In addition, overlap is observed with diabetes type 1 signaling. This kind of 
signaling originates from incomplete hormone response between the liver and the kidney[110]. 
All three of these pathways were identified due to the measured decrease expression of CASP3 
and MHC I. MHCI is one of many known upstream indicators of all three pathways, and CASP3 
is a common downstream indicator of pathway activation. CASP3 inhibition is also an indicator 
of cell survival as its activation is necessary for apoptosis[111]. These pathways of overlap 
reflect a PHPT1 overexpression phenotype which is thriving and prepared for an oxidative 
stress response, and a heterozygous phenotype that seems to be reacting to an external stress 
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already. The only difference between the two cell types is the initial expression levels of PHPT1 
and the resulting potential change in phosphohistidine modifications. 
Conclusions 
 The significance of phosphohistidine signaling in mammals is yet to be fully understood. 
Despite its likelihood of being highly utilized in key pathways and functions, it remains one of 
least understood phosphorylation modifications, especially compared to phospho- serine, 
tyrosine, and threonine. Implications of further understanding the role of phosphohistidine 
signaling go beyond just understanding cellular mechanisms. Phosphohistidine has been shown 
to play roles in various diseases, including many forms of cancers [52, 53, 66, 67, 112] and 
pancreatic diseases such as type II diabetes [46]. In this investigation, we created and 
characterized much-needed animal models for investigating the role of PHPT1-mediated 
phosphohistidine signaling.  
 Adenoviral-based constructs have previously been shown as effective tools for inducing 
liver-specific overexpression of a protein of interest. In our study, we effectively used this to 
create a liver-specific PHPT1 overexpression model. This model shows a significant increase in 
PHPT1 overexpression that can be maintained for several weeks (see Chapter 4: Expression 
Validation). In addition, the creation of the PHPT1 overexpression model requires very little time 
and provides an easily reproducible method for inducing PHPT1 overexpression. Our 
characterization of this model provides insight into the impact decreased phosphohistidine 
levels have on liver homeostasis. In addition, these data provide a reliable control to compare to 
treated PHPT1 overexpression models. The ease and specificity of this method gives it the 
potential to be utilized for organ-specific siRNA mediated knockdown, in addition to 
overexpression. We intend to apply this method for liver-specific PHPT1 knockdown in future 
studies.  
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 However, we did create and characterize a knockout model employing the Cre-mediated 
recombinant heterozygous mice provided by the KOMP repository at UC Davis. We validated 
the genomic expression and translational expression of PHPT1 in this model across multiple 
tissues. We demonstrated that this model is a valid animal-wide PHPT1 heterozygous knockout. 
Further characterization of liver tissue from this model was done to create a direct comparison 
with our overexpression model. This characterization provides two benefits: we now have a 
base model for experimental comparison and we gained insight into the influence of increasing 
phosphohistidine signaling on an organism-wide level.   
We also determined for the first time that PHPT1 is an embryonic lethal knockout in 
C57BL/6J mice through offspring genotyping and Mendelian genetic comparisons. This 
discovery adds to the potential importance PHPT1 has in cell regulation and highlights it is a 
necessary protein during embryonic development. PHPT1 is part of the Janus family of proteins 
which are well characterized in Drosophila melanogaster as proteins involved in sex 
differentiation and development. So, it is likely PHPT1 may have similar roles in mammalian 
development that have yet to be determined. Furthermore, PHPT1 overexpression has been 
shown to be involved in EMT in cancer cells [67]. This study further suggests that PHPT1 and 
phosphohistidine are involved in regulating cell differentiation. A complete PHPT1 knockout 
could be disturbing the fragile differentiation of cells during development, leading to embryonic 
lethality. Further investigation of the mechanisms involved in PHPT1-induced embryonic 
lethality are needed.  
Most importantly, characterization of these two models reveals PHPT1 expression has a 
wide range of influence on cellular functions. It appears that overexpression and knockout of 
PHPT1 impacts cellular function through distinct mechanisms that do not coincide. PHPT1 
knockout experiments in cell cultures have been shown previously to influence ACL expression 
[45], and cell movement [51]. Furthermore, PHPT1 overexpression studies, have been 
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correlated to cell viability [45], cell proliferation [66], and insulin regulation [46] via ACL function. 
Our study shows a great amount of overlap in expression targets with these mechanisms. 
However, we reveal varying signaling pathways induced by PHPT1 overexpression versus the 
heterozygous mouse model. Further investigation into how PHPT1 expression is interacting with 
the downstream targets is necessary to better understand the significance of phosphohistidine 
signaling in the mammalian liver. 
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Chapter 4 – The influence of PHPT1 expression on ethanol-induced hepatic steatosis 
during chronic ethanol exposure 
Summary 
 Following characterization of both the PHPT1 overexpression and knockout models, 
further investigation of the influence of PHPT1 expression on ethanol-induced hepatic steatosis 
was investigated. Initial studies of the 10-day chronic plus binge ethanol mouse model 
confirmed the model validity. Overexpression of two key ethanol response proteins CYP2E1 
and EPHX1 were identified (Figure 8a). In addition to model validation, this initial study 
determined PHPT1 expression to be significantly decreased following chronic ethanol exposure 
(Figure 8b). Further model validation was reflected by the formation of lipid droplets and 
hepatocyte ballooning seen in the ethanol-treated mouse livers but not in the pair-fed control 
mice (Figure 9). This discovery led us to further investigate the influence of PHPT1 expression 
on the onset of alcoholic liver disease and elucidate possible upstream regulators and canonical 
pathways involved in phosphohistidine signaling.  
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 Both the PHPT1 overexpression and PHPT1 knockout models were administered the 
10-day chronic plus binge ethanol exposure model and livers were collected for phenotype 
characterization. Samples from each treatment group were analyzed for disease progression 
markers such as AST, ALT, triglyceride levels, and blood alcohol concentration. Samples were 
also taken for H&E staining to assess the development of steatosis. PHPT1 expression 
validation was also performed post treatment. Finally, mass-spectrometry based phenotypic 
characterization was done using label free quantitation of liver lysates to determine significantly 
differentially expressed proteins following ethanol response and between PHPT1 expression 
cohorts. This information was used to determine upstream regulators and canonical pathways 
involved in phosphohistidine signaling during chronic ethanol exposure. 
 Experiments revealed that PHPT1 overexpression mice had a decrease in circulating 
triglycerides and a lower development of steatosis, which was assessed via independent 
pathology scoring, than the ethanol treated GFP overexpression control group.  However, our 
PHTP1 heterozygous mice showed additional susceptibility to developing high triglyceride levels 
and the onset of steatosis. This result was reflected by similar phenotypes observed between 
the heterozygous control groups which were provided a higher-fat controldiet with no ethanol, 
and our wild-type ethanol groups. Both groups demonstrated significantly high triglyceride levels 
and large amounts of hepatocyte ballooning and lipid droplet accumulation. In addition, the 
heterozygous control group showed increased inflammation and necrosis around the vascular 
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islets in the liver.  This result was also observed in the heterozygous ethanol treated samples, 
but not in the wild-type control samples. This information suggests PHPT1 expression correlates 
with the onset of liver steatosis, and possibly plays a role in the development of ALD and non-
alcoholic fatty-liver disease (NAFLD).  
 To further understand the mechanism by which PHPT1 is influencing the development of 
fatty liver disease, we performed advanced mass-spectrometry based phenotypic 
characterization. Proteomics allowed us to take a snapshot of the global proteome following the 
control and ethanol treatments and to quantify changes in protein expression between 
(patho)physiological states. Furthermore, it also allowed validation of PHPT1 expression and 
disease progression. Our analysis found that PHPT1 expression was consistently decreased, in 
the range of 20-60%, following ethanol exposure regardless of its initial expression levels. 
Furthermore, bioinformatic analysis predicted PHPT1 expression to influence susceptibility of 
ethanol-induced hepatic steatosis. This susceptability is predicted to be mediated through 
PPARα/ RXRα pathway regulation as well as regulation of cytochrome P450s via ABCB6 
signaling and other transcriptional regulators. These pathways are known players in ethanol 
metabolism and ROS response [13]; however, they have not previously been shown to be 
involved in phosphohistidine signaling. Although further validation of these targets is necessary 
to fully understand the mechanism of PHPT1 and phosphohistidine signaling in these pathways, 
it is clearly apparent that PHPT1 expression is playing a novel role in liver injury susceptibility. 
Introduction 
Ethanol-induced hepatic steatosis 
The progression and severity of ALD has been widely discussed previously 
(Introduction: Alcoholic liver disease). As mentioned previously, the progression of this disease 
begins with the onset of fatty liver or more specifically ethanol-induced hepatic steatosis. The 
development of this phenotype is characterized primarily by the histological changes that take 
place in hepatocytes. These changes are induced by overactivation of ethanol metabolism 
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pathways and result in dramatic changes in lipid homeostasis and cell signaling [11]. 
Hepatocytes perform the primary role of the liver to remove toxins from the blood stream. Given 
this, hepatocytes are well suited with a plethora of metabolites and anti-oxidant proteins to 
compete against moderate ethanol exposure [113]. However, chronic ethanol exposure will 
interfere with normal ethanol metabolism. This interference occurs in multiple ways, including 
ROS oxidation, changing in the acetyl-CoA pool, and disruption of fatty acid oxidation [11]. The 
metabolism alterations directly create visual changes in hepatocyte histology. Development of 
hepatocyte ballooning and Mallory bodies occurs as a result of the increase in fatty acid 
production and decrease in fatty acid β-oxidation [13]. In addition, hepatocyte stress leads to 
recruitment of the resident liver immune cells, Kupffer cells, which release inflammation causing 
cytokines and interferons [19]. This change results in further liver damage. Often this damage is 
initially present exclusively surrounding the portal veins where blood first interacts with the liver. 
However, as these cells become deactivated due to over exposure, this phenotype spreads to 
the rest of the liver. This damage combined with efforts to replace and repair damaged cells 
leads to liver swelling, which is often the earliest identified symptom of ALD [13]. However, at 
this point, fibrosis is occurring, and the development of early stage hepatitis is occurring. At this 
stage, the potential for minimally invasive full recovery is significantly lower than during initial 
hepatosteatosis [2]. Unfortunately, without a biopsy, hepatosteatosis is generally asymptomatic. 
Further understanding in how this disease develops and finding novel mechanisms influenced 
by chronic ethanol exposure will aid in early identification and prevention.  
Mouse models of ethanol feeding 
 The mouse model has been an exemplary one used to study the onset, progression, and 
impact of ALD for many years. During this time, many models of exposure have been developed 
for understanding different facets of disease progression [78]. These exposure models vary by 
focus of study in the progression of ALD. Models which are developed to look simply at animal 
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behavior or habituation often give the mouse a choice between ethanol consumption and not 
[114]. Models looking for short-term exposure or studying the immediate impact of ethanol on 
the organism will often employ a gavage ranging from 10-1 g ethanol/kg bodyweight depending 
on the desired severity of the binge. This range gives blood ethanol concentrations (BEC) from 
0.5 g/dl to 0.05 g/dl, respectively. Another binge model that has been recently developed uses 
ethanolinfused gelatin to encourage quick but less forceful consumption [115]. Furthermore, 
there are many models which investigate the impact of long term or chronic ethanol exposure. 
These models range from a multichoice consumption [116], to a purely ethanol supplemented 
diet [77], and even a normal chow but using ethanol vapor to provide consistent ethanol 
exposure [117]. These models usually aim at inducing reproducible severity of alcoholic liver 
disease while at the same time having a relevant control that is exposed to the same 
environmental factors but not ethanol. This accomplishment can be challenging considering the 
caloric burden and stress ethanol consumption has on an organism.  
 The model we choose to use is the 10-day chronic plus binge ethanol model, which 
consists of a liquid 5% ethanol diet for 10 days and is concluded with a 5 g ethanol/kg body 
weight gavage [77]. The control groups from this model also receive a liquid diet which contains 
the same calorie contents and are given a gavage supplemented with maltose dextrin equal in 
calories/volume to that of the ethanol diet. This model is well characterized in creating moderate 
to severe liver steatosis (Figure 8). This phenotype is validated by H&E stained liver sections 
developing motifs such as hepatocyte ballooning, lipid droplet, and Mallory body formation 
(Figure 9) [77]. In addition, liver injury is characterized further by showing an increase in the 
amounts of circulating ALT, AST, and triglyceride levels as compared to the pair-fed controls. In 
human models, the ratio of AST/ALT levels have been shown to indicate severity of ethanol-
induced liver injury [118]. However, in the mouse model, significant upregulation of either of 
these metabolites are considered a marker of ALD [77]. We have also verified that known 
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ethanol-induced expression changes are taking place on proteins such as CYP2E1 and EPHX1 
(Figure 8a), which are both known to be upregulated following chronic ethanol exposure [24]. It 
was also found the PHPT1 expression levels are down regulated following the exposure model 
as well (Figure 8b). This led us to investigate further how expression of PHPT1 is influencing the 
onset of this liver injury.  
Materials and Methods 
10-Day chronic plus binge ethanol diet 
 PHPT1 expression altered, eGFP induced, and wild-type C57BL/6 mice were split into 
cohorts for ethanol or control diet treatments. Male and female mice were used for the 
heterozygous and wild-type cohorts and only male mice were used for the PHPT1 and eGFP 
overexpression models. Each cohort initially consisted of 3-10 mice per treatment type. This 
model was based on the publication of Bertola et al [77] using the Lieber DeCarli liquid diet 
formula. In brief, ethanol-treated mice received a liquid diet that was 5% vol/vol ethanol as their 
only source of nourishment. Control mice received a liquid diet as well that did not contain 
ethanol but was equivalent in calories per serving. Consumption of this diet was monitored for 
both groups over 10-days to ensure consistent intake occured between pair-fed groups. 
Following the 10th day of consumption, ethanol treated mice received a 5 g/kg ethanol/body 
weight gavage with a 31.5% vol/vol ethanol solution. Control mice receive a gavage consisting 
of 9g/kg maltose dextrin/body weight with a 45% wt/vol solution. Mice were then sacrificed 
9hours later and their blood alcohol concentration, AST, ALT, and triglyceride levels were tested 
to determine disease severity.  
Fluorescence microscopy  
 Florescence microscopy was carried out on formaldehyde-fixed tissue sample slides 
prepared by the Moffitt Tissue core. Samples that were not stained were provided and used to 
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determine eGFP expression via fluorescent excitation. Slides were first treated with a DAPI 
nuclear counterstain solution (Pierce) to stain the nuclear envelope. This was most effective on 
single cells near the edge of the formaldehyde-fixation area. Slides were viewed using an 
UtlraVIEW ERS spinning disk confocal microscope (Perkin Elmer) with a solid-state laser 
emission at 405nm and image capturing was performed using the Velocity software set to the 
same parameters for all samples. This instrumentation was provided generously by the CMMB 
core facilities.  
Western blotting 
 Lysates were derived from control and ethanol diet-treated mouse livers and were 
analyzed by western blot to verify PHPT1 expression levels. Western blot analysis was carried 
out using TGX any KD gels (Bio-Rad) followed by a semi-dry transfer to either nitrocellulose or 
PVDF membranes. Nitrocellulose membranes were ponceau stained immediately following 
transfer for confirmation of equivalent loaded total protein. PHPT1 was probed for using a 1:500 
dilution in 5% BSA of the N-23 anti-PHPT1 antibody (SC-130229, Santa Cruz). A 1:5000 dilution 
in milk of the HRP conjugated goat anti-rabbit secondary (Cell signaling technology) was used. 
Development was carried out using SuperSignal chemiluminescent reagent (Thermo scientific) 
and signal intensity was measured on the AI600 (LICoR) instrument. 
Histology 
 Immediately following sacrifice, liver tissue sections were taken for paraffin-embedding 
and hematoxylin and eosin staining. Tissue sections were taken from the center of a large lobe 
of liver tissue and from pair-fed animals in each treatment group. Paraffin-embedding, 
formaldehyde-fixation and H & E staining was performed at the Moffitt Cancer Center Tissue 
Core Histology services. Tissues were then analyzed to identify histological motifs of hepatic 
steatosis including the development of lipid droplets, Mallory bodies, hepatocyte ballooning, and 
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inflammation. Steatosis scoring was performed on tissues when available based on the 
presence of these factors. Samples were formaldehyde-fixed to slides and analyzed under 40X 
magnification using a DM2000 upright fluorescent microscope (Leica) with the SPOT camera 
and SPOT basic software (Spot imaging) and keeping settings consistent between samples.  
Clinical chemistry 
 Animal serum was removed immediately where approximately 200 ul of whole blood was 
acquired from each animal and aliquoted for determining metabolite concentrations. Serum was 
tested for ALT, AST, and circulating triglyceride levels by either assay kits (Point Scientific Inc.) 
according to the manufacturer’s instructions on a PowerWave XS (BioTek) microplate reader 
shortly after extraction, or it was sent to the Moffitt College of Medicine Vivarium, which used an 
IDEXX Vettest chemistry analyzer. Metabolite levels where compared between treatment types 
and sexes to determine relationship of disease state and fold change in metabolite levels.  
Blood ethanol concentration 
 Blood ethanol concentration of each mouse was also quantified using blood serum 
samples. This method was performed using the BEC kit (Sigma-Aldrich). In brief, serum was 
spun from the blood samples and 5 µl was diluted at 1:10 for the quantification. BEC standards 
were analyzed in duplicate and both a negative and positive control was included in triplicate. 
Each sample was tested in triplicate after adding the activating enzyme and sample absorbance 
was read on a PowerWave XS (BioTek) microplate reader. Sample concentration varied from 
0.005-0.5 g/dl. This concentration translates directly to BEC levels with anything less than 0.08 
g/dl considered insignificant and greater than 0.08 g/dl consistent with the binge ethanol 
consumption model. BEC levels were tested for all mice in which enough serum was able to be 
extracted.  
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Label free quantitation of ethanol treated mouse liver samples 
 Mouse liver samples were obtained from each cohort immediately following the 
conclusion of ethanol treatment and sacrifice. Livers were preserved by cryo freezing and 35-40 
µg biopsies were used for protein extraction. Following homogenization, lysis took place using a 
4% SDS, 100 mM DTT, 100 mM Tris-HCl, pH 7.4 at 95° C for 5 minutes. Total protein was 
quantified using the Pierce 660 assay method supplemented with an ionic detergent 
compatibility reagent (IDCR) (Pierce). Equal amount of protein was taken from each sample 
(150 µg) for detergent removal using the FASP method [75]. In brief, samples were washed 
three times with 8 M Urea on a 30 kDa filtered column (Corning). Proteins were then alkylated 
using 100 mM iodoacetamide and another buffer exchange was performed to prepare for 
Trypsin digestion in 50 mM ammonium bicarbonate. Mass spec grade Trypsin/Lys-C was added 
at a 1:50 ratio to protein for digestion overnight at 37° C. Peptides were then extracted for desalt 
on Sep-Pak C18 columns on a Supelco Vacuum manifold. Finally, peptides were dried and 
resuspended in MS-grade 0.1% formic acid.  
 Samples were analyzed on a Q-Exactive plus (Thermo Fischer) in-line with an Ultimate 
3000 HPLC (Thermo Fischer). Separation was performed on a 75µm X 50cm reversed phase 
analytical column, packed with Pepmap100, 3 µm, 100 Å C18. This analytical column was 
followed by a 75 µm X 2 cm cap trap packed with Pepmap100, 3 µm, 100 Å C18. Samples were 
run on a 120 min gradient from 2% to 50% B (0.1% formic acid in acetonitrile). Full MS survey 
scans were performed with a maximum resolving power of 70,000 and 17,500 for MS/MS 
resolution. Data dependent analysis was performed selecting the top 10 most abundant 
peptides for MS/MS CID fragmentation analyses with a dynamic exclusion time of 20 seconds. 
Sample from the same experiment were analyzed concurrently with blanks and quality controls 
included throughout the sequence.  
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 High-resolution raw MS data files were searched against the Mus musculus Uniprot 
database using MaxQuant (1.6.0.16, maxquant.org) search algorithm. Label free quantification 
parameters were selected for data normalization in MaxQuant to ensure consistency between 
samples. Search parameters also included a first search peptide tolerance of 20 ppm and a 
main search peptide tolerance of 4.5 ppm with a false discovery rate of less than 1% and overall 
localization probabilities of ≥95% for modified peptides. The resulting normalized protein 
abundances were used for statistical analysis.  
 Statistical filtering began with removal of any protein that was not observed in at least 
two thirds of a single treatment group. All intensities were then log2 transformed for statistical 
analysis. Perseus software (1.6.0.7, http://www.perseus-framework.org/) was used to determine 
imputation values, for samples without intensity values, that did not influence the expression 
distribution of the data. A Welch’s t-test was performed between treatment types with a 
significance threshold of a p-value <0.05. In addition, a Z-score was calculated to determine the 
significance of the Welch’s t-test difference between samples and provide further statistical 
stringency [76]. Analysis between treatment groups was performed by utilizing a ratio of ratios 
between treatments and models. To fully elucidate the influence of PHPT1 expression on 
development of ethanol-induced hepatic steatosis, alike variables between groups had to be 
offset. This analysis was completed by determining the fold change differences between the 
control and ethanol groups of the wild-type models and PHPT1 expression-influenced models 
individually. These ratios were then compared to each other to determine factors that were only 
affected by the amplified or reduced expression of PHPT1, following ethanol exposure.  
To determine possible mechanisms involved in phosphohistidine signaling that are 
affecting the development of ethanol-induced hepatic steatosis, we uploaded the significantly 
influenced fold-changes to IPA for a core analysis. This program uses our identified fold-change 
expression differences to predict regulators, canonical pathways, and disease states being 
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activated/inhibited, based on their known relationships. This kind of analysis is known as a core 
analysis and searches the database for all known protein interactions. Analytical data provides a 
p-value of overlap and z-score of activation for significance. The p-value of overlap represents 
the likely hood of overlap in targets identified from the data and a regulator or function known to 
interact with those targets in the IPA database. The z-score represents the likelihood of 
activation or inhibition of the predicted pathway based on its interactions with the uploaded data. 
To further understand the mechanisms involved in phosphohistidine signaling following ethanol 
treatment core analysis of the significantly differentially expressed proteins were performed. 
Then comparisons between PHPT1 expression models was performed by either taking a ratio of 
ratios or by comparing the core analyses of the two models directly to each other, using the 
comparison analysis feature, to differentiate regulators and pathways uniquely influenced from 
those activated independently of PHPT1 expression. This program provided bioinformatic 
insight for determining pathways being influenced by PHPT1 expression that have yet to be 
identified. Using IPA to determine potential targets is an especially invaluable tool in the case of 
phosphohistidine signaling. Unfortunately, more conventional ways of targeted identification are 
far more difficult in the case of phosphohistidine signaling due to its extremely labile nature.  
Results and Discussion 
Expression validation 
 For the Ad-PHPT1 and Ad-GFP mouse model’s initial validation that liver-specific 
expression remained following the 10-day chronic ethanol exposure was performed. This 
validation was done using ELISA and microscopy data to assess eGFP expression and western 
blot data to quantify PHPT1 expression. Additionally, mass-spectrometry data was also used to 
verify increase expression of both proteins when performing the global proteomic investigation. 
EGFP expression was shown to remain constant between the control and ethanol-treated 
samples and showed no significant expression in the Ad-PHPT1 samples (Figure 10a). 
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Furthermore, fluorescence microscopy was used to visualize the eGFP expression in the Ad-
GFP livers. This method was also performed on Ad-GFP spleen tissue and Ad-PHPT1 liver 
tissue as negative controls. Only the Ad-GFP liver tissue displayed green fluorescence 
indicative of eGFP expression (Figure 10b-d).   
 All mice fed ethanol-containing diet were validated for PHPT1 expression following 
treatment. PHPT1 overexpression samples were compared directly to the eGFP overexpression 
counterpart and heterozygous samples were compared directly to the wild-type mice. PHPT1 
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expression levels were initially shown to increase 3-fold between the Ad-PHPT1 overexpression 
and Ad-GFP models, and we began with a 2-fold decrease between the wild-type and 
heterozygous model (Chapter 3: Figure 6). Ad-PHPT1 and Ad-GFP samples were analyzed 
using western blot analysis after ethanol or control diet exposure (Figure 10e). This result 
revealed a consistent overexpression of PHPT1 as compared to the eGFP, following exposure 
of both the ethanol and control diets. This result was consistent with our mass spectrometry 
LFQ data (Figure 10c). PHPT1 expression levels were significantly greater than that of the 
eGFP throughout all experimental factors. We did not, however, observe significant decrease in 
PHPT1 expression between the ethanol and control mice in either the Ad-GFP or Ad-PHPT1 
groups. In addition, the decrease of PHPT1 expression in the wild-type group following ethanol 
treatment still remained higher than the PHPT1 expression of the control heterozygous mice 
(Figure 10d and f). This result means that these mice began with PHPT1 levels below that of 
normal ethanol downregulation. In addition, there was a consistent decrease in PHPT1 
expression between control and ethanol-fed mice in the western blot data (Figure 10f). A 
significant ethanol-induced decrease in PHPT1 expression was observed in both the wild-type 
and heterozygous groups (Figure 10f). 
Disease state 
 Tissues from each treatment and expression group were analyzed for disease 
progression in using various techniques. Samples from each group were tested for ALT, AST, 
and circulating triglyceride levels in the blood using clinical chemistry. In addition, blood ethanol 
concentrations were determined for each mouse, provided a sufficient amount of blood was 
available, to verify effectiveness of the gavage. Pair-fed mice had liver tissue biopsies removed 
to be paraffin-embed and H&E stain to determine steatosis scores and immunohistochemical 
analyses. Mass spectrometry data were also used to verify increased expression of the known 
alcohol-induced liver injury markers, CYP2E1 and EPHX1.  
 BECs from the mice were between 0.005-0.040 g/dl for the control mice and 0.14-0.20 
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g/dl for the ethanol-treated mice. This result shows a significant increase in BEC levels following 
treatment, as expected. Furthermore, AST and ALT levels were expected to be elevated in the 
ethanol-treated mice as compared to the control-fed mice. This result was observed for both 
ALT and AST in the Ad-GFP mice and the female wild-type mice as seen in Figure 11a & b. 
However, no significant changes were observed between treatments for any other samples. The 
measurements for the Ad-GFP and Ad-PHPT1 samples were taken using different methods and 
instruments than the heterozygous and the wild-type samples. This inconsistency in methods 
could potentially alter the average quantity of the measurements taken, considering the 
sensitivity of the two separate methods used varied. Triglyceride (TAG) levels were also 
investigated using various methods (described in Chapter 4: methods). Circulating TAG levels 
were expected to increase following chronic ethanol exposure and as a result of liver injury 
development. A significant increase in TAG following ethanol treatment was observed in all 
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samples except for the female heterozygous serum (Figure 11c & d). In addition, TAG levels 
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were significantly lower in the Ad-PHPT1 ethanol treated sample that in the Ad-GFP sample. 
This suggests PHPT1 overexpression is decreasing the amount of TAG levels produce in 
response to ethanol. The opposite of this was observed in our female heterozygous model 
where measured TAG levels were pre-elevated in the control sample and remain that way 
through the ethanol treatment. 
 Additional disease phenotyping was performed immunohistochemically using H & E-
stained paraffin-embed livers from pair-fed mice. Ad-GFP and Ad-PHPT1 livers were scored 
based on steatosis development using a scale of 0- normal, 1- mild, 2- moderate, and 3-severe. 
Three liver samples were scored from each treatment and the average score was determined 
and shown in Figure 11c. As expected, the Ad-GFP control sample showed a mild score and 
ethanol treatment induced a severe steatosis score for the treated samples. The control Ad-
PHPT1 samples, however, were scored as normal while steatosis development following 
ethanol treatment was only mild. This scoring is reiterated in the histology of the Ad-PHPT1 and 
Ad-GFP samples as seen in Figure 11a & b. Both the Ad-PHPT1 and Ad-GFP samples show 
very few (if any) hepatocyte ballooning and lipid droplet formations, which are common 
hallmarks of steatosis (Figure 12a) [77]. Ethanol-treated Ad-GFP mice show extensive 
hepatocyte ballooning, and lipid droplets in approximately 60% of the hepatocytes, which is 
indicative of hepatosteatosis. In the ethanol-treated Ad-PHPT1 mice, however, very little to no 
hepatocyte ballooning is observed and lipid droplets appear in less than 30% of the hepatocytes 
(Figure 12). This histological pattern suggests PHPT1 overexpression is playing a protective 
role in the development of fatty liver. PHPT1 heterozygous and wild-type samples were not able 
to be officially scored for steatosis. However, in-house histological analysis of the H & E stained 
samples was performed to assess the severity of liver injury (Figure 12). The wild-type control 
and ethanol-treated mice show similar results to that of the Ad-GFP samples, which is expected. 
This result is reflected by a development of lipid droplets in approximately 40% of the 
hepatocytes in the ethanol-treated group and none in the control. However, in the heterozygous 
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mice, we observed lipid droplet formation and inflammation in both the ethanol-treated and 
control groups (Figure 12, black and yellow arrows). Lipid droplet formation is consistently 30-
40% confluent in both the heterozygous and wild-type ethanol-treated groups. However, 
inflammation in the heterozygous control and ethanol samples appears more severe compared 
to the wild-type groups (Figure 12, yellow arrows). This difference was seen consistently 
throughout histological tissue assessments. Development of inflammation and steatosis during 
the control treatment suggests an increase susceptibility to hepatic steatosis induced by 
decreased expression of PHPT1. 
Phenotypic characterization 
 To further understand the mechanisms involved in the role of phosphohistidine signaling 
and PHPT1 during chronic ethanol exposure, we used mass spectrometry-based proteomics to 
characterize the phenotypes induced by each treatment type in each model. This analysis was 
accomplished by determining significantly differentially expressed proteins between the control 
and ethanol treatment in each model. Then a full core analysis was performed in IPA to 
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determine regulators, canonical pathways, and diseases related to the proteins identified as 
significantly changed. Finally, the attributes identified were directly compared to each other 
using a comparison analysis to determine trends between all three expression levels, 
overexpression, wild-type, and heterozygous. Using this method, we identified potential 
mechanisms and regulators of phosphohistidine regulation for further investigation.  
 The top pathways, diseases, and regulators identified are displayed in table 3. These are 
accompanied by the calculated z-scores for each, which signify the level of activation/inhibition 
that is predicted to occur. A z-score of greater 2 or less than -2 is indicative of significant 
activation of inhibition, respectively. Pathways are listed by largest change between 
heterozygous and overexpression z-score. The largest of these changes in the canonical 
pathways is the PPARα/RXRα activation. This pathway is predicted to be significantly inhibited 
in the heterozygous model and not in the overexpression group. This pathway is involved in lipid 
homeostasis and specifically in regulating β-oxidation of lipids for exportation [119]. A decrease 
in this pathway would result in greater susceptibility to steatosis. In addition, PHPT1 
downregulation was predicted to activate multiple signaling pathways, all of which are related to 
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G-protein mediated signaling. This activation may be related to the regulation of G-protein 
activation by phosphohistidine. Also, NRF2-mediated oxidative stress response is active in both 
the over expression and heterozygous conditions. This pathway would be expected to be 
activated following ethanol exposure [120].  
 The top upstream regulator identified is ABCB6 and is predicted to be activated in the 
overexpression and wild-type group but inhibited in the PHPT1 heterozygous model (Table 3). 
This molecule is an ATPase binding cassette that plays a crucial role in heme synthesis and 
porphyrin transport [121]. Protein expression changes identified can be seen in the outer nodes 
of Figure 13a and b, which was used to determine predicted activation/inhibition of ABCB6. In 
both treatment types, the predominate enzymes involved in this prediction are cytochrome 
P450s that were downregulated in the heterozygous model and upregulated in the 
overexpression model. Cytochrome P450 regulation, in addition to steroid metabolism, are 
additional functions of ABCB6 [122]. The heterozygous model is predicted to activate MYC 
which is a well characterized oncogene involved in cell cycle regulation and angiogenesis 
(Table 3) [104]. MYC activation can lead to dysregulation of the cell cycle and often results in 
cell death via apoptosis [123]. PHPT1 overexpression is predicted to activate NR1I3 and 
ethanol as well. Both regulators are expected to be activated following ethanol response, as 
NR1I3 is a nuclear receptor involved in xenobiotic regulation [124]. In addition, NR1I3 is 
involved in RXRβ and alcohol dehydrogenase 3 regulation [124]. These regulators are not 
predicted to be activated in the heterozygous model.  
Conclusion  
 No change in PHPT1 expression levels between the control and ethanol groups in the 
Ad-GFP and Ad-PHPT1 samples was unexpectedly observed. This observation, however, could 
be due to the limitation of sensitivity whilst analyzing expression levels with such a high dynamic 
range between them. In a side-by-side western blot analysis, the high intensity of PHPT1 in the 
Ad-PHPT1 samples, over-saturate the blot, making the wild-type PHPT1 levels difficult for 
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accurate detection. This same limitation in sensitivity was observed in the mass spectrometry 
samples in which PHPT1 intensity levels are upwards of 100-fold higher than the Ad-GFP 
samples. This dynamic range makes accurate quantification of PHPT1 in either sample difficult. 
Efforts to use a method with a much higher dynamic range were taken, however, were also 
either unsuccessful or not able to be completed. A PHPT1 ELISA kit was attempted but did not 
perform up to company standards based on its own internal controls and standards. The 
availability of additional PHPT1 ELISA kits is scarce due to the limitation of study that has been 
performed on this protein. In addition, absolute quantification could be accomplished using 
targeted mass spectrometry via either a triple-quadrupole instrument using single/multiple 
reaction monitoring or using the Q-Exactive parallel reaction monitoring (PRM) feature. 
Contrary, the heterozygous samples showed only 50% less in PHPT1 expression than the wild-
type. This expression difference made the dynamic range for quantification much more 
attainable via western blot where total protein quantities could be increased to adjust for low 
protein concentrations. This adjustment allowed us to observe the expected significant decrease 
between treatments as shown in Figure 10f. With PHPT1 expression already low compared to 
many other natural liver proteins, PHPT1 expression was still difficult to quantify accurately 
using unfractionated total lysate samples with LC-MS/MS analysis using a 2-hour gradient in-
line with an Orbitrap mass spectrometer. Utilizing a targeted method for PHPT1 quantification 
on a triple quad or using the PRM feature on the Q Exactive could have allowed for more 
accurate PHPT1 expression assessment [125, 126].  
 Nonetheless, PHPT1 expression ratios between models were consistent throughout 
treatments. This result provided us three consistent expression profiles for characterizing the 
role of PHPT1 during chronic ethanol exposure. Additional challenges included, disease 
prognosis where consistency among ALT, AST, and histology scoring was not obtained. These 
challenges were not without attempted solutions either. The ALT and AST scores were originally 
performed according to the NIAAA chronic plus binge model guidelines. The assay kits used 
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were the ones recommended by the guidelines [77], however, their success rate, even with their 
own standards, were low. Accordingly, we used a core facility with a high specificity instrument 
to obtain measurement the second time. Unfortunately, inconsistencies were observed for these 
samples as well due to the limitations in whole blood quantities obtained from the animals. 
However, these tests did provide us insight on changes in circulating TAG levels. This change is 
significant given the proteomic information found relating heavily to lipid homeostasis. 
Furthermore, professional steatosis scoring was only performed on the overexpression groups. 
This variation was due to that service no longer being available by the time the heterozygous 
treatment was performed. Therefore, scoring and histology assessment of these samples had to 
be performed in house. Although, not official, the assessments of histological markers of 
steatosis development were able to be identified based on numerous publications documenting 
hepatic steatosis injuries.  
 Even with the multiple challenges pertaining to disease phenotyping, we were able to 
conclude confidently that PHPT1 overexpression led to a milder disease progression than the 
wild-type, and heterozygous expression levels made the organism more susceptible to steatosis 
onset even without ethanol treatment. This result makes understanding the mechanisms behind 
the role of PHPT1 during chronic ethanol exposure even more vital. Using global proteomic data 
to determine significantly differentiated proteins between disease states allows us to determine 
possible pathways being influenced by PHPT1 expression. Making sense out of the colossal 
amount of data provided by mass spectrometry data is immensely easier to do using a software 
program such as IPA. This analysis gives investigators specific pathways and mechanisms to 
focus on to determined precisely what PHPT1 functions is influencing.  
 Our IPA data revealed multiple potential mechanisms of PHPT1 response to ethanol. 
Canonical pathways of significance include the PPARα/RXRα inhibition following ethanol 
treatment in the heterozygous model. The mechanism of this type of inhibition is unknown but 
the phenotype coincides with our other disease phenotype data. Inhibition of the PPARα/RXRα 
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would lead to a decrease in fatty acid β-oxidation resulting in lipid accumulation [32]. This 
mechanism is known to occur during chronic ethanol exposure [127], however, this is occurring 
in the heterozygous model independent of ethanol exposure (Figure 12). Significant inhibition of 
this pathway was only seen in the model with decreased PHPT1 expression. In addition, the 
heterozygous model showed activation of multiple pathways dependent on G-protein activation. 
PHPT1 has been shown to play a regulatory role in G-protein activation through the β-subunit 
phosphohistidine phosphorylation [37]. G-protein activation is involved in many cellular 
pathways and it is interesting that only these three would be influenced by a decrease in PHPT1 
expression. Dysregulation of these specific pathways is known to be involved in abnormal cell 
cycle regulation (Rac [128] and CXCR4 [129]) and inflammation (Integrin [130]). Overactivation 
of these pathways is only seen in the heterozygous model. This overactivation again, coincides 
with inflammation and abnormalities seen in both our control and ethanol-treated heterozygous 
groups (Figure 12). These results are further supported by the predicted activation of MYC in 
the heterozygous model. MYC is a well characterized oncogene involved in cell cycle regulation, 
that often leads to cell death if dysregulated [123]. Hepatocyte cell death would induce an 
immune cell response and, if not impeded, would result in an inflammatory response [131].  
 The only mechanism that is predicted to be significantly activated during overexpression 
and inhibited in the heterozygous model is ABCB6 (Table 3). This result is interesting because 
ABCB6 functions as an ATP-binding cassette and has no known affiliations with 
phosphohistidine or ALD, however, it is known to be involved in other liver diseases [120]. 
ABCB6 inhibition has been known to negatively affect human health in a variety of diseases 
[132]. Other ATP-binding cassettes have also been shown to be involved in ROS removal and 
protection [122]. These studies would support the predicted results that ABCB6 inhibition is 
creating a more susceptible phenotype and activation would assist in a protective role against 
chronic ethanol exposure. Contrary to this finding, however, ABCB6 overexpression has also 
been seen consistently in hepatocellular carcinomas and is believed to be a result of disease 
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progression from steatosis to carcinoma [132]. In addition, ABCB6 has not been directly 
associated with chronic ethanol exposure or ethanol-induced hepatic steatosis previously. This 
association would make this mechanism a novel and impactful one to further investigate based 
on its predicted functions in chronic ethanol exposure response through phosphohistidine 
signaling.  
 These studies have provided a newfound insight on the significance of phosphohistidine 
signaling and PHPT1 in the onset of a universally contracted disease. Phosphohistidine 
modifications are potentially influencing previously known and unique mechanisms involved in 
the development of ALD. Our study has provided clear evidence that increased PHPT1 
expression levels correlate with a milder response to chronic ethanol exposure, and decreased 
expression correlates with a higher susceptibility to steatosis and inflammation. In addition, we 
have identified numerous potential pathways through stringent statistical filtering and 
bioinformatic analysis that could be leading to this correlation. It is evident that there is much 
more to know about the role of phosphohistidine signaling in alcohol-induced liver injury and 
potentially other mechanisms of disease pathogenesis.  
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Chapter 5 – Conclusions and Future Directions 
Conclusions 
Overview 
 The initial development of ALD from a healthy liver to the onset of sometimes irreversible 
hepatoseatosis is poorly understood. There are many proposed mechanisms involved, including 
dysregulation of CYP2E1 [90] in the ethanol metabolism pathway, as well as increase in 
inflammatory [17] mechanisms through the JAK/STAT pathway, and loss of lipid homeostasis 
via PPAR (α and γ) [127]. However, more detail is needed about this mechanism to understand 
how these different pathways are affected by ethanol. This information is vital because early 
detection and treatment of ALD is critical in preventing development of more serious forms, 
such as cirrhosis, hepatitis, and eventually liver failure. Currently, hepatosteatosis is virtually 
asymptomatic and can only be diagnosed following a liver biopsy [11]. This obstacle leads to 
most cases of ALD being diagnosed either post-mortem or beyond the point of recovery. A 
deeper investigation into the mechanistic details of disease onset is necessary to better detect 
the early development of this disease. 
 Initial studies that were performed identified a potential novel player in ethanol 
metabolism. PHPT1 was identified as a target of ethanol-induced oxidation in an acute 
exposure model and identified to be downregulated in the chronic mouse model. Furthermore, 
the significance of PHPT1 phosphatase activity was poorly understood but it shared an 
overlapping target with ethanol metabolism, ATP-citrate lyase (ACL) [35]. PHPT1 is known to 
regulate ACL function [45] and ACL is a key regulator of the acetyl-CoA pool that is often 
dysregulated by increased ethanol metabolism [133]. There are believed to be many additional 
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targets of phosphohistidine phosphorylation that have yet to discovered as well [56]. This theory 
makes PHPT1 a probable novel regulator in the onset of ethanol-induced hepatosteatosis.  
 To investigate the significance of PHPT1, we initially focused on the oxidation 
modification induced by acute ethanol treatment. Our studies showed that although PHPT1 
oxidation increased by 2-fold, there was no change in PHPT1 expression following acute 
exposure. This result led us to characterize the location and extent of oxidation on PHPT1 and 
to determine the modification’s impact on phosphatase function. These studies were carried out 
using human recombinant PHPT1, and by developing a mass spectrometry-based 
phosphohistidine phosphatase assay. This investigation led us to discover that although PHPT1 
was being selectively oxidized at Met95, which is a vital residue in substrate binding, it is not 
influencing PHPT1 phosphatase activity. Next, we further investigated the role PHPT1 
expression was playing during chronic ethanol exposure models. 
 To understand the role of PHPT1 in ethanol induced hepatosteatosis, we used a mouse 
model to provide more biologically relevant information than cell cultures or recombinant 
proteins. This mouse model was treated for 10-days with the Lieber DeCarli diet composed of 
5% ethanol mixed in with mouse chow in a liquid diet form. The control mice were also given a 
liquid diet, but it was supplemented with dextrose instead of ethanol to maintain caloric 
consistency between the two groups. Protocols were followed according to the NIAAA 10-day 
chronic ethanol plus binge model [77]. C57BL/6J mice were provided only the liquid diet for 
consumption over the course of 10 days. The level of consumption from each mouse was 
recorded and tracked daily. At the end of the 10-day period, the mice were given a gavage of 
5g/kg (ethanol/body weight) 9 hours prior to sacrificing. Control mice were administered maltose 
dextrin (9 g/kg in water) instead of ethanol. Mouse livers were removed and used for 
determining the extent of ethanol induced liver damage using histology, steatosis scoring, and 
proteomics. Blood ethanol concentration (BEC) and clinical chemistry measuring AST, ALT, and 
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TAG levels were also assessed based on the blood samples.  This method was used for all the 
chronic ethanol studies with varying strains of mice.  
 The initial study, which used the same wild-type male mice for the control and ethanol 
treated group, was performed to create a baseline and determine the significance of PHPT1 in 
wild-type mice. The BEC levels for the ethanol-treated mice were significantly higher than the 
control. The clinical chemistry performed showed a greater increase in AST, ALT, and TAG 
levels in the ethanol treated mice as well. Histology steatosis scoring reflected moderate to 
severe steatosis in ethanol treated mice samples, in comparison with mild to moderate in the 
control samples. Furthermore, mass spectrometry-based proteomics showed an increase in 
both EPHX1 and CYP2E1, as well as other indicators of ethanol induced hepatosteaosis in the 
ethanol-treated groups [24]. This proteomic analysis also identified PHPT1 expression as being 
significantly decreased in the treated samples by 2-fold. These results provided validation for 
the model in that it created a diseased state organism that differed from the control. It also 
allowed us to identify PHPT1 expression as significantly influenced following ethanol-induced 
hepatosteosis, making it a potential player in the disease onset. To further investigate this, we 
developed a PHPT1 liver-specific overexpression model and a PHPT1 knockout model.  
 PHPT1 overexpression was accomplished using an adenoviral-based vector coded with 
PHPT1 and an albumin promoter. This experiment was done in comparison to the same 
construct but with an eGFP sequence for amplification instead of PHPT1. This virus was 
injected intravenously with an albumin promoter for targeted expression in the liver. C57BL/J6 
mice were sacrificed 5-days following injection to verify expression change. EGFP expression 
was verified using microscopy, ELISA, and mass spectrometry-based proteomics. PHPT1 levels 
were verified using western blot and proteomics as well. Expression levels were compared 
between tissue types (liver and spleen) to determine organ specificity, and between constructs 
(eGFP and PHPT1). EGFP expression was only identified in the Ad-eGFP animal’s liver through 
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proteomic analyses and ELISA. Microscopy showed no expression of eGFP in the PHPT1 livers 
or in other tissues such as the spleen. PHPT1 expression was shown to be increased 3-fold in 
liver tissue compared to the Ad-GFP livers by western blot, and expression was increased 18-
fold as determined by proteomic analysis. PHPT1 expression in either cohort’s spleen tissue 
remained the same.   
 The knockout PHPT1 model was requested from the UC Davis KOMP repository. This 
mouse was genetically altered using Cre recombination to create a non-conditional knockout 
lacZ gene in a C57BL/6J mouse. These mice showed heterozygous expression of PHPT1 and 
the lacZ recombinant gene. Mice were bred over many generations, and they were genotyped 
using PCR and phenotyped using western blot, to confirm expression profiles. Genotypes were 
confirmed by PCR using a PHPT1 (WT) primer and a lacZ (KO) primer. Following multiple Het-
Het cross (N>20) and genotyping of each viable offspring (N=128), we identified no 
homozygous knockouts. Using a chi-square test, we determined with a 99% confidence that this 
inheritance pattern did not follow that of Mendelian genetics. We then validated protein 
expression using western blot analysis of multiple tissue types to determine PHPT1 expression. 
We found that PHPT1 expression was decreased by an average of approximately 50% in each 
tissue analyzed from the heterozygous mice, as compared to the wild-type.  
Following validation of the expression profiles, liver samples from each PHPT1 
expression model were used for mass-spectrometry based phenotypic characterization. These 
models were then compared to wild-type mice of the same age and origin. Expression changes 
between each model and the complementary control model were then compared to determine 
any consistencies between all three models (Wild-type, PHPT1 overexpression, and PHPT1 
heterozygous). This investigation found a significant p-value of overlap with both the over 
expression mouse model changes, and the heterozygous model changes, with upstream 
regulators involved in hormone-regulated transcriptional activation and with a cell cycle 
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regulatory molecule. Although, p-value of overlap was significant for both expression models, 
the proteins identified in each model that overlapped with the upstream regulator shared very 
few similarities. This result suggests different mechanism being influenced by PHPT1 
overexpression as compared to the knockout.  
 Furthermore, each expression model showed significant p-values of overlap with unique 
canonical pathways. The targets predicted to be influenced by PHPT1 overexpression were 
glycogen, and S-methyl-5'-thioadenosine degradation. These are both involved in preparation of 
cell replication [134] and inflammatory pathways [135]. Overexpression also shows overlap with 
α-tocopherol degradation, which signifies an increase in β-oxidation and excess antioxidant 
production [108]. Alternatively, we see overlap in the heterozygous model with two pathways 
signaling immune response-mediated cell death and the type 1 diabetes signaling pathway. The 
identified pathways suggest that the PHPT1 overexpression cells are better suited for an 
external stress, whereas the heterozygous cells seem to be undergoing a stress response 
already, presumably induced by a decrease in PHPT1 expression.  
Ethanol Studies 
 Following the development and characterization of the PHPT1 expression models, we 
determined how PHPT1 expression is influencing the onset of ethanol-induced hepatic 
steatosis. This investigation was carried out using the 10-day chronic plus binge ethanol 
consumption model [77]. In each case, mice were pair-fed with a control which consumed a 
dextrose supplemented diet without ethanol at a similar rate to that of the ethanol fed mouse. 
These mice were immediately sacrificed 9 hours after the gavage given on the 10th day, and the 
livers were removed for analysis. To determine the influence of PHPT1 on ethanol-induced liver 
damage, each cohort underwent a variety of tests to determine the disease progression and the 
changes in proteomic expression levels. We also, validated PHPT1 expression differences 
between the models following the ethanol treatment using western blot, and proteomic analysis.  
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 First, treatment validation was performed by testing the BEC. In addition, clinical 
chemistry of the mouse blood for circulating AST, ALT, and TAG levels was conducted to 
determine the initial changes in liver function following ethanol and control treatments. We did 
expect to see some increase in the control mice due to the high caloric intake, but the largest 
increase should be in the ethanol fed mice. Next, disease progression was determined using 
H&E staining and scoring for steatosis. Pair-fed mouse livers were selected for paraffin-
embedding and formalin-fixed for H&E staining. Slides were then analyzed for steatosis scoring 
to determine the extent of ethanol-induced liver damage. Images of slides were taken as well, to 
be scored and analyzed for steatosis markers, such as lipid droplet formation, hepatocyte 
ballooning, and inflammation. Disease onset and treatment validation was also performed by 
quantifying known proteomic markers. Furthermore, PHPT1 expression was validated using 
western blot and LFQ intensity values from all samples. These data confirmed a consistent 
difference in PHPT1 expression levels, regardless of treatment type, between models. 
Additional expression validation was performed on the Ad-GFP samples using an ELISA, which 
provided absolute quantification. ELISA data reiterated that time or treatment type did not 
influence the expression of eGFP in the Ad-GFP samples. 
 Last, we performed mass spectrometry-based phenotypic characterization on all treated 
samples from all the PHPT1 expression models. Significant differentially expressed proteins 
were identified based on their LFQ intensity values and calculated using stringent statistical 
filtering. Fold-changes of identified significantly changed proteins were then uploaded to IPA for 
core analysis, to determine predicted regulators and canonical pathways influenced by PHPT1 
expression. These results were compared between models, to determine differences in PHPT1 
expression influence. Our results revealed that the PHPT1 heterozygous expression model is 
predicted to inhibit PPARα/RXRα pathway, while activating integrin, CXCR, and RAC signaling 
pathways. PPARα/RXRα inhibition would result in a decrease in fatty acid β-oxidation, which 
75 
 
leads directly to increased lipid accumulation. In addition, activation of the integrin pathway 
relates to cell signaling of many forms including adhesion, activation, or inflammation [130]. 
Whereas, Rac pathway activation leads to cytoskeletal rearrangement or cell cycle progression 
[128], and CXCR activation is known to relate with immune response [129] and has been 
associated with MYC-induced cancer progression [136]. This coincides with the predicted 
activation of MYC in the heterozygous model, as well. MYC is a known oncogene [104] involved 
in regulating cell survival pathways [123]. 
 Alternatively, PHPT1 overexpression is predicted to activate the upstream regulator 
NR1I3 and ABCB6. NR1I3 activation would increase the RXRβ pathway, increase production of 
alcohol dehydrogenase, and is a protective protein during xenobiotic response [137]. Both 
NR1I3 and ABCB6 are regulators of cytochrome P450s, which are essential in ethanol exposure 
response [15, 121, 122, 124, 137]. The heterozygous PHPT1 model was predicted to inhibit 
ABCB6 activation, thus decreasing the xenobiotic response. These prediction models along with 
our disease phenotype data demonstrate that PHPT1 overexpression is playing a protective role 
against ethanol-induced liver injury, and the PHPT1 heterozygous model is more susceptible to 
liver damage.  
Future directions 
 The completion of this study has brought about significant advances in understanding 
the contribution of a poorly characterized protein in a novel role. In addition, this study has 
provided new ways to investigate the enzymatic activity of PHPT1 and discovered, for the first 
time to the best of our knowledge, that a PHPT1 complete knockout results in early embryonic 
lethality. We have displayed a strong correlation with PHPT1 expression levels and 
susceptibility to fatty liver disease develop that has never been published before. Finally, we 
have suggested multiple novel pathways and mechanisms that phosphohistidine signaling is 
influencing in mammalian cells.  Although the accomplishments of this study are significant, 
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there is much more to be done in order to fully understand the role of PHPT1 and 
phosphohistidine signaling in the onset of ALD.  
Additional Mouse models 
 Ideally, more animal studies would have been utilized to fully understand how and why 
PHPT1 expression was influencing ethanol-induced liver injury. Our overexpression and 
heterozygous mouse showed the extreme conditions of PHPT1 expression, but many more 
questions are left to be answered following the investigation of these two models. Unfortunately, 
a complete animal wide knockout was not possible due to the embryonic lethality of the allele. 
However, it is possible to create a liver-specific siRNA-mediated knockout using an adenoviral 
based vector. In addition, an investigation using the liver-specific overexpression vector on the 
heterozygous model would show if a phenotypic rescue was possible. Furthermore, creation of 
an enzymatically inactive PHPT1 overexpression model would aid in determining if PHPT1 
phosphatase activity was influencing disease progression or if this was being done through an 
alternative mechanism. The PHPT1 H52A mutant could be used in the viral construct just as in 
the Ad-PHPT1 overexpression. In addition, creating a PHPT1 rescue model using the Ad-
PHPT1 virus to rescue the heterozygous would assist further in linking PHPT1 expression to 
ethanol-induced liver injury development. The means and materials to create these models and 
characterize their phenotype before and after ethanol treatment is available [138], and they 
would provide much greater insight into how phosphohistidine signaling is involved in injury 
onset.  
Lipidomic analysis 
Given the significant overlap in PHPT1 expression and numerous lipid homeostasis 
pathways, an in depth lipidomic analysis of tissues with varying PHPT1 expression and ethanol 
treatment would provide critical insight into the mechanisms of phosphohistidine signaling. It is 
already well known that lipid oxidation and metabolism are affected by chronic ethanol exposure 
[17]. This effect occurs via a combination of ethanol-induced insults including that of ROS [11] 
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and endoplasmic reticulum stress [13]. Oxidative stress combined with ethanol’s inhibition of 
AMPK activation, leads to an increase in fatty acid and lipid production in hepatocytes, mediated 
by SREBP1-C [13]. Concurrently, ethanol causes a decrease in fatty acid β-oxidation via 
PPARα inhibition through oxidative stress [28]. This inhibition results in an increase in cellular 
fatty acids and creates the hepatocyte ballooning effect and lipid droplet formation commonly 
seen in liver histology [28]. This response is well characterized during chronic ethanol exposure; 
however, our data suggests that PHPT1 is influencing this response.  
Our PHPT1 expression characterization data suggests phosphohistidine signaling is 
involved in key transcriptional regulatory pathways such a 17β-estradiol signaling, MYC 
activation, and other hormonal signaling pathways (See Chapter 3: results). Based on the 
ethanol studies (See Chapter 4: results), this seems to create a phenotype that is either better 
prepared for ethanol stress, in the case of PHPT1 overexpression, or more susceptible to 
development of steatosis, in our heterozygous model. This susceptibility was further shown by 
predicted inhibition of pathways, such as the PPARα/RXRα in the heterozygous models, and 
change in expression levels of key fatty acid metabolism enzymes, such as FABP4 and FABP5 
in both models [139]. This overlap in PHPT1 expression levels with fatty acid metabolism 
enzymes and pathways suggests phosphohistidine signaling influences lipid homeostasis, 
following ethanol exposure. This trend was further validated by the steatosis scoring and 
histological staining performed on treated tissues, which showed a significantly lower 
development of steatosis for the tissues that were overexpressing PHPT1 than those at wild-
type levels. In addition, histology showed tissues with the heterozygous genotype had greater 
steatosis development and lipid droplet formation induced by an increased calorie diet alone in 
the control groups. Tissues from mice treated with ethanol showed similar severity in damage 
between the heterozygous and wild-type. To further understand how PHPT1 is influencing the 
creation and regulation of these lipids, a lipidomic analysis of these tissues would be necessary.  
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Shotgun lipidomics is similar in technique to shotgun proteomics, in that it analyzes 
many forms of the biological molecule at one time [140]. This method would allow us to take a 
snapshot of the types of lipids being expressed in our various models of PHPT1 expression and 
disease state. This method is beneficial in that it would give us an idea as to which lipids are 
being influenced and would provide direction to further investigate specific lipid families [141]. 
However, the limitations of this method coincide with its robustness. The highly complex lipid 
molecules are often very abundant and usually lead to high degrees of overlap in parent ion 
mass between multiple lipid types [142]. This makes it far more difficult to quantify a specific 
conformation when no isolation or fractionation has occurred prior to analysis. The 
implementation of shotgun lipidomics would be the first step in analysis, and it will determine 
which lipid classes should be isolated for further investigation in each sample.  
Following identification of lipid targets, ideally, we would be able to isolate and determine 
expression changes in these targets between cohorts. Quantification would be accomplished 
using parallel reaction monitoring (PRM) on the Q-Exactive hybrid Orbitrap instrument [126]. 
This instrument allows us to specify a parent ion mass and the product ions created from it by 
fragmentation to monitor intensity levels and quantify lipid classes specifically. PRM allows us to 
specify multiple parent ion targets (lipid classes) for quantification from the same sample 
simultaneously [126]. Targeted lipidomics via PRM will provide reliable and reproducible 
quantification of the lipids present in each sample to determine how their synthesis is influenced 
in each cohort, and it will provide additional insight into the mechanism of phosphohistidine 
signaling influencing lipid homeostasis.  
Mechanistic Validation 
The use of mass spectrometry to determine protein expression changes between 
treatment groups is currently a widely excepted method among many scientific fields [76, 143-
147]. Instrumentation has advanced significantly over the past 20 years and provides highly 
reliable and reproducible results, which can be further solidified by technical or biological 
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replicates (See Chapter 1: Mass spectrometry-based proteomics). Regular instrumental 
maintenance and internal controls and standards contributes significantly to generating high 
resolution and high mass accuracy data. Samples should also be analyzed concurrently with 
multiple replicates, quality controls, and blanks included before, during, and after the sequence 
to maximize reproducibility. In addition, database search parameters should be set with high 
stringencies and low mass tolerance variabilities, as well as low false discovery rates to further 
insure high-resolution data is being correctly matched with the peptides and proteins they 
originate from [76]. Furthermore, stringent unbiased statistical analysis following identification 
decreases the false discovery rate, and accuracy is increased further by only accepting proteins 
identified in a majority of the biological replicates from a single cohort. All of these steps are 
taken in the previously described experimental methods (Chapter 3: Methods; Chapter 4: 
Methods) to ensure high quality accurate data, reflecting a snapshot of the proteomes under 
investigation. Thus, making western blot, or other validations of mass spectrometry-identified 
protein expressions, complementary but not a necessity.  
However, further validation of the predicted influenced pathways identified through IPA is 
necessary to further understand the mechanisms being influenced by phosphohistidine 
signaling, during chronic ethanol exposure. Many of the identified pathways or upstream 
regulators are either regulated independently of protein expression, or instrumentation is not 
able to identify them due their expression levels or the sample’s complexity. Regulation of this 
type includes post translation modifications, conformational alterations, or ligand binding. All 
mechanisms of regulation and specific protein expression can be verified using methods such 
as western blot, phosphoproteomics, immunoprecipitation, and many other methods specific to 
the regulatory element. Specifically, to verify the deactivation of the PPARα/RXRα pathway, 
predicted to be inhibited in the heterozygous ethanol treated mice, a western blot could be used 
to determine changes in PPARα expression levels as well as changes in one of the many 
downstream targets of PPARα, such as FABP1 [148]. In addition, activation of PPARα/RXRα 
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requires the formation of a heterodimer [137]. PPARα and RXRα co-localization can be 
determined using immunohistochemistry via antibodies against each protein. Furthermore, fatty 
acid β-oxidation is the downstream effect of PPARα/RXRα activation [149]. The levels of β-
oxidation can be measured to validate inhibition or activation using one of many fatty acid β-
oxidation assays available. Validation of all the predicted upstream regulators and pathways is 
necessary to better understand the mechanisms of PHPT1 regulation.  
Targeted search for phosphohistidine phosphatase proteins 
It is apparent from our findings that PHPT1 and phosphohistidine signaling play a much 
larger role in ethanol response in the liver than previously believed. It is very likely that this 
novel role is mediated through previously unidentified targets of phosphohistidine regulation. 
The next step in further understanding this mechanism is determining what proteins are directly 
targeted by phosphohistidine and influenced by PHPT1 expression and activity. However, 
identifying these targets in not an easy feat. The challenges of isolating and identifying 
phosphohistidine modified proteins are still difficult to overcome, even with modern scientific 
techniques. One improvement to the challenge, is the development of a pan-phosphohistidine 
antibody, specific for N-1 or N-3 phosphohistidine modification[60]. Development of this 
antibody was only made possible using a phosphohistidine analogs with higher stability than the 
modification [150, 151]. The developed antibody claims to bind only to proteins with the 
specified phosphohistidine modification (N-1 or N-3) [152]. This antibody has been tested in our 
lab with some success. Therefore, if the targets are accurate, western blot analysis using this 
antibody shows a great deal of phosphohistidine targets that have yet to be characterized. 
There is also a potential for this antibody to be used in an immunoprecipitation experiment, to 
isolate only those proteins that contain phosphohistidine modification. Proteins can then be 
characterized using mass spectrometry-based proteomics to determine their identity. 
Furthermore, an additional co-immunoprecipitation experiment can be performed using PHTP1 
as the target and the identified phosphohistidine-containing proteins as the potential ligands. 
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This experiment could help determine if any of these targets of phosphohistidine are also 
targets of PHPT1. Confirmation of this type can be achieved for specific proteins using the mass 
spectrometry-based phosphohistidine phosphatase assay, previously described in this text 
(Appendix A: Scientific Reports). Furthermore, mass spectrometry methods have been 
developed to identify phosphohistidine-modified proteins based on neutral losses during CID 
[153]. Using this method, two novel sites of phosphohistidine modification including aldehyde-
alcohol dehydrogenase were determined. This discovery potentially creates another link 
between PHPT1 expression and chronic ethanol exposure.  
Identifying novel targets of phosphohistidine and PHPT1 would be beneficial in not only 
further understanding the role of phosphohistidine during ethanol exposure, but these targets 
could also lead to a better understanding of the role of PHPT1 in normal cellular functions [60]. 
PHPT1 has been identified in numerous diseases, including cancers, but often the pathways 
and mechanisms associated with its expression differ depending on the cell type [46, 66, 67, 
112, 154]. These studies lead us to believe phosphohistidine signaling and PHTP1 regulation of 
this modification is playing a diverse role in cellular functions. A better understanding of this role 
would be accomplished by determining a more comprehensive list of phosphohistidine and 
PHPT1 targets.  
Human tissue analyses  
The question of translational relevance is always considered when using any model. In 
our case, the mouse model was the closest organism we could use for ethanol studies and still 
be able to create the PHPT1 overexpression and heterozygous genotypes in a relatively short 
time frame. However, human samples are always the end goal. Although altering the expression 
levels and disease state of a human sample would not be possible, there are currently human 
liver samples available which have known patient backgrounds and have developed varying 
states of ALD. These tissues are available by request from the Ibrahim El-Hefni liver 
biorepository and California Pacific Medical Center. Liver samples were taken from patients who 
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had a range of ALDs varying from mild steatosis up to severe late stage hepatitis. A majority of 
the samples, however, are from patients in the later stages and from individuals with 
backgrounds of existing liver disease, or familial history, making them less likely to fit the 
requirements for our study. This outcome is most likely due to the initial asymptomatic 
progression of the disease, making early onset very difficult to detect unless an existing liver 
disease is already present [11]. 
Nonetheless, human tissues could provide additional insight into the role of PHPT1 in 
progression of human ALD. It would not be difficult to screen the expression levels of PHPT1 in 
various disease states, and normal levels of PHPT1 expression in human liver tissue is already 
available. The human tissue aspect of this investigation would be the final step in validating any 
mechanism identified in the mouse model in human liver tissues. Therefore, although these 
tissues are currently available, it would make most sense to obtain them following all previously 
described experiments to make the most out of the sample provided. Human tissues could 
immediately be screened for other targets of PHPT1 and phosphohistidine identified, and for 
phosphohistidine modifications using the same methods described previously (Chapter 5: 
targeted search for phosphohistidine phosphatase proteins). Human tissue analyses would 
provide high confidence in terms of overall relevance of PHPT1 and phosphohistidine signaling 
in ALD pathogenesis, and these samples would provide a novel avenue of study on the role of 
phosphohistidine in mammalian cellular processes.   
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